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Glioblastoma (GBM) is an aggressive form of brain cancer that has a high recurrence rate 
and very poor prognosis. The prognostic value of various molecular markers (e.g., IDH-1 
mutation, MGMT promoter methylation, etc.) and clinical factors (e.g., age, KPS, surgery 
and chemotherapy) has been studied in GBM after initial diagnosis but not as extensively 
in the recurrent GBM. Utilizing a retrospective cohort design, based on quantitative data 
collected through medical chart reviews, and the conceptual framework of outcomes 
research in oncology, this study evaluated the prognostic value of IDH-1 mutation in 
recurrent GBM in the context of key predictor variables of age, MGMT promoter 
methylation, KPS, and surgery and chemotherapy at recurrence. The study specifically 
evaluated if there was a significant difference in overall survival and progression free 
survival between rGBM patients with and without IDH-1 mutation and if selected 
molecular and clinical covariates affected these outcomes. The results of this study 
indicated, albeit with its limitations, that IDH-1 mutation was not a prognostic factor in 
recurrent GBM. The prognostic value of IDH-1 mutation from initial diagnosis in this 
study was inconclusive, consistent with previous reports. The results of this study also 
indicated that although methylated MGMT promoter was a strong prognostic factor from 
initial diagnosis as previously reported, it was not a prognostic factor in recurrent GBM. 
Overall, the results of this study suggest that the prognosis and treatment of GBM may 
need to be considered differently at initial diagnosis and following disease recurrence. It 
is anticipated that the results of this study will bring about a positive social change by 
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Chapter 1: Introduction to the Study 
Glioblastoma (GBM) is by far the most frequent malignant glioma. It is 
associated with a particularly aggressive course and a dismal prognosis (Ostrom et al., 
2014). Glioblastoma is characterized by symptoms including slow progressive 
neurological deficit, weakness in motor skills, headache, increased intracranial pressure, 
and seizures (Ostrom et al., 2014). The tumor location may be indicated by these 
neurological symptoms as well as by focal signs, including hemiparesis, sensory loss, 
visual loss, and aphasia (Ostrom et al., 2014). Extremely rapid cell infiltration is a key 
biological feature of glioblastoma; tumor cells travel to other sites within the brain, which 
makes it very difficult to completely remove tumors through surgery (Olar & Aldape, 
2014). Therefore, in conjunction with inadequate response to treatment, the recurrence 
rate is very high with GBM, resulting in poor overall prognosis (Li et al., 2015). Newly 
diagnosed GBM subjects have a median overall survival (mOS) of 12 to 15 months and a 
2-year-overall survival (OS) rate of up to 27% (Omuro et al., 2013). Subjects who have 
experienced multiple recurrences, referred to as recurrent GBM (rGBM), have a 
particularly poor prognosis, with a mOS of 6 to 7 months. The OS in subjects who have 
failed temozolomide (TMZ) and bevacizumab, or equivalent salvage chemotherapy, is as 
short as 3 to 5 months (Iwamoto et al., 2009; Omuro & DeAngelis, 2013). 
According to the National Cancer Institute’s Surveillance, Epidemiology, and End 
Results (SEER) database, there are an estimated 166,039 people living with brain and 
other nervous system cancers in the United States in 2015 (Cancer of the Brain and 




indicates that there are currently 700,000 Americans living with a brain tumor, of which 
560,000 are benign and 140,000 are malignant (Quick Brain Tumor Facts, n.d.). Given 
that gliomas comprise approximately 80% of all malignant brain tumors (Quick Brain 
Tumor Facts, n.d.), the prevalence of malignant gliomas in the United States is 
approximately 112,000. The 5-year survival rate for GBM is estimated at 5.6%; survival 
decreases if the disease is diagnosed at an older age (Ostrom et al., 2018). 
Glioblastoma is more common in older adults. The median age at diagnosis is 65 
years and the incidence rate is highest in adults aged 75-84 years (Ostrom et al., 2018). 
While the incidence rate is 1.6 times higher in males, the frequency of secondary GBM is 
higher in females, with a male-to-female ratio of 0.65 (Ostrom et al., 2018; Thakkar et 
al., 2014). The incidence rates of malignant brain and other central nervous system (CNS) 
tumors are higher in Whites (7.62 per 100,000 persons) than Blacks (4.52 per 100,000 
persons) and the incidence rate of GBM is approximately two times greater in Whites 
than Blacks (Ostrom et al., 2018). There are no well-established environmental or 
behavioral risk factors associated with brain or CNS tumors except exposure to ionizing 
radiation (Ostrom et al., 2018); however, the risk of developing a brain cancer is twice as 
high in individuals who have a parent, child, or full sibling diagnosed with brain cancer 
(Ostrom et al., 2018). 
Isocitrate dehydrogenase-1 (IDH-1) mutation status is now used in the 
classification of gliomas, based on an understanding that IDH-1 mutant and wild-type 
gliomas have different underlying tumor biology and therefore need to be treated 




surgical resection is typically used in the treatment of glioma patients. Clinical data have 
showed benefits from the aggressive treatment of glioma patients with IDH-1 mutation, 
making upfront and initial treatment with RT and chemotherapy a standard of care for 
patients with IDH-1 mutant Grade II and III gliomas (Miller et al., 2017). Because the 
role of IDH-1 mutation in rGBM is not well understood, it is difficult to determine 
whether similar upfront aggressive treatment would confer any significant benefit to the 
patients, given the risks associated with RT and chemotherapy. Hence, this study 
specifically addressed this gap in research on the potential role of IDH-1 mutation in 
rGBM, with the aim to improve disease prognosis and survival outcome in GBM and 
rGBM patients. It is anticipated that the results of this study will help GBM patients and 
their treating physicians make a more informed decision about the most appropriate 
treatment regimen for managing the disease. After general background on GBM, this 
chapter addresses the problem statement and purpose of the study along with specific 
research questions. The conceptual framework of the study is briefly described followed 
by study limitations, expected significance of the study, and overall chapter summary.   
Background 
Glioblastoma is an aggressive form of brain cancer that has very poor prognosis 
(Ostrom et al., 2018). It is difficult to completely remove tumors through surgery, and the 
cancer cells rapidly infiltrate other parts of the brain (Olar & Aldape, 2014); therefore, 
GBM has a very high recurrence rate, which, in conjunction with inadequate response to 
existing treatment, results in poor prognosis. The mOS for rGBM is 6-7 months; the mOS 




(Iwamoto et al., 2009; Omuro & DeAngelis, 2013). IDH-1 mutation status is now used to 
classify gliomas, based on the understanding that IDH-1 mutant and wild-type gliomas 
have different underlying tumor biology and therefore need to be treated differently 
(Miller et al., 2017). 
Waitkus et al. (2016) provided a review of IDH mutations in gliomas, including 
information about the biochemistry and effects of IDH mutations. They also highlighted 
the utilization of IDH mutations as putative biomarkers for glioma, including its potential 
role in disease prognosis and treatment outcomes (Waitkus et al., 2016). 
Calvert et al. (2017) and Labussiere et al. (2010) underlined the role of IDH 
mutation in GBM (Calvert et al., 2017; Labussiere et al., 2010). Calvert et al. highlighted 
the upregulation of wild-type IDH-1/2 in GBM, while Labussiere et al. showed a four-
fold longer survival among GBM patients with an IDH-1 mutation than among those with 
wild-type IDH-1. 
Amelot et al. (2015), Mukasa et al. (2012), and Zou et al. (2013) provided 
different views of the controversy over the prognostic value of IDH mutation in GBM 
(Amelot et al., 2015; Mukasa et al., 2012; Zou et al., 2013). For example, while Amelot 
et al. identified IDH mutation as a weak prognostic factor for survival, Mukasa et al. 
indicated that, at least in Grade III gliomas, IDH mutation was associated with long-term 
survival. The meta-analysis conducted by Zou et al. also supported the prognostic value 
of IDH mutation in GBM. 
Taal, et al. (2014) and Mandel et al (2016) noted the paucity of knowledge about 




conducted on this topic (Mandel et al., 2016; Taal et al., 2014). Moreover, the studies 
conducted on rGBM included a total of only 10 patients with IDH-1 mutation, so they 
indicated that the results of these studies must be interpreted with caution (Mandel et al., 
2016; Taal et al., 2014). Considering that the role of IDH-1 mutation as a prognostic 
factor remains controversial, even at initial diagnosis, more studies are needed, 
particularly in rGBM, to understand the role of IDH mutations in this disease. 
Problem Statement 
Glioblastoma is one of the most common types of malignant gliomas and has an 
aggressive disease course and very poor prognosis (Ostrom et al., 2018). GBM may 
manifest at any age, but it typically affects adults at age 45-84 (Ostrom et al., 2017; 
Ostrom et al., 2014). IDH-1 gene mutation has been extensively studied as a prognostic 
factor in GBM following initial diagnosis, but it has not been studied as much in rGBM 
(Amelot et al., 2015; Mukasa et al., 2012; Ostrom et al., 2018). The prognostic value of 
IDH-1 mutation is debated even following initial diagnosis of GBM: studies have 
demonstrated both weak and strong association between IDH-1 mutation and overall 
survival (Amelot et al., 2015; Mukasa et al., 2012; Zou et al., 2013). A few studies have 
examined the role of IDH-1 mutation in rGBM, but only in the clinical trial setting and 
with inconclusive results (Mandel et al., 2016; Taal et al., 2014). These studies suggest 
that patients with IDH-1 mutated tumors show an improved trend in overall survival at 
first recurrence; however, in rGBM trials, IDH-1 mutation did not result in prolonged 
progression-free survival or overall survival compared to IDH-1 wild-type tumors 




included only a total of 10 patients (five patients in each study) with IDH-1 mutation. The 
authors indicated that the results of these studies must be interpreted with caution, given 
the very small sample size, and suggested additional studies be conducted to better 
understand the role of IDH-1 mutation in rGBM (Mandel et al., 2016; Taal et al., 2014). 
IDH-1 mutation status is now used in the classification of gliomas, given the 
understanding that IDH-1 mutant and wild-type gliomas have different underlying tumor 
biology and therefore need to be treated differently (Miller et al., 2017). A combination 
of RT, chemotherapy, and surgical resection is typically used in the treatment of glioma 
patients (Wick et al., 2018). Even though the long-term side effects of RT and 
chemotherapy were initially questioned, particularly in low grade gliomas, over the years 
clinical data has shown benefits from aggressive treatment of glioma patients with IDH-1 
mutation (Czapski et al., 2018; Kazda et al., 2018; Paolillo et al., 2018; Zang et al., 
2018). This has made initial upfront treatment with RT and chemotherapy a standard of 
care for patients with IDH-1 mutant Grade II and III gliomas (Miller et al., 2017). 
Because the role of IDH-1 mutation in rGBM is not well understood, it is difficult to 
determine whether similar upfront aggressive treatment would confer any significant 
benefit to patients, considering the risks associated with RT and chemotherapy. This 
study addressed this gap in research and evaluated the potential role of IDH-1 mutation in 
rGBM, with an aim to improve disease prognosis and survival outcomes in rGBM 
patients. It is anticipated that the results of this study will help rGBM patients and their 
treating physicians make more informed decisions about the most appropriate treatment 




Purpose of the Study 
The purpose of this study was to determine whether IDH-1 mutation is a 
prognostic factor in rGBM considering other molecular and clinical prognostic factors as 
covariates. In a retrospective cohort study, time to first recurrence from initial diagnosis 
and time to disease progression or death from first recurrence was evaluated in GBM 
patients with IDH-1 mutated and wild-type tumors. The effect of key variables (i.e., O-6-
methylguanine-DNA methyltransferase (MGMT) promoter methylation, age, Karnofsky 
performance score (KPS), surgery for resection, and chemotherapy at progression) on 
correlation between IDH-1 mutation status and disease progression and survival was also 
evaluated. The study also estimated the overall prevalence of GBM as a type of nervous 
system cancer at the participating hospitals in Massachusetts. 
Research Questions and Hypotheses 
RQ1: Is there a significant difference in time to disease progression and overall 
survival after first recurrence between rGBM patients with IDH-1 mutation and those 
without IDH-1 mutation? 
H01: Based on IDH-1 mutation status, there is no statistically significant 
difference in the time to disease progression and/or overall survival of rGBM patients. 
H11: Based on IDH-1 mutation status, there is a statistically significant difference 
in the time to disease progression and/or overall survival of rGBM patients. 
RQ2: Is the correlation between IDH-1 mutation status and disease progression 
and survival after first recurrence affected by the covariates of MGMT promoter 




H02 – The correlation between IDH-1 mutation status and disease progression and 
survival is not affected by covariates MGMT promoter methylation, age, KPS, surgery 
for resection, and chemotherapy at progression. 
H12 - The correlation between IDH-1 mutation status and disease progression and 
survival is affected by covariates MGMT promoter methylation, age, KPS, surgery for 
resection, and chemotherapy at progression. 
Conceptual Framework for the Study 
The aims and scope of the study were congruent with the conceptual framework 
of outcomes research. The goal of outcomes research in oncology is to improve medical 
practice in order to achieve better outcomes in patients (Lee et al., 2000). Outcomes 
research draws on multiple specialties and subspecialties of clinical science to better 
understand the effectiveness of treatments and to enable clinicians to make more 
informed decisions (Lee et al., 2000). In oncology, outcome research addresses a broad 
range of questions and oncology-related endpoints, such as overall survival (OS) and 
progression-free survival (PFS), which are studied utilizing administrative databases and 
cohort or case-control study designs (Lee et al., 2000). This conceptual framework is also 
supported by other researchers, who are increasingly advocating that outcomes research 
in oncology is more than health services research per se and that outcomes research 
requires an integrated multidisciplinary approach in order to understand the complexity 
of tumorigenesis and factors that impact patient outcomes (Apolone, 2003; Fay et al., 
2015; Kovvali, 2014; Melamed et al., 2017; Roberts et al., 2019). This study, from the 




parameters of research and applications of outcomes research (Lee et al., 2000). First, the 
purpose of this study, to determine whether IDH-1 mutation is a prognostic factor in 
rGBM, broadly fits the treatment options and prediction rules of the outcomes research 
framework because IDH-1 mutation is an important prognostic factor that informs 
treatment options. Second, the study utilized clinical outcomes like OS and PFS that are 
suggested in the outcomes research framework (Lee et al., 2000). Furthermore, the 
application aspect of the outcomes research conceptual framework suggests that the 
research should lead to clinical or policy decisions (Lee et al., 2000). It is anticipated that 
the results of this study will inform clinical decisions in terms of treatment 
recommendations and clinical practice guidelines for the management of rGBM patients, 
using IDH-1 mutation as a prognostic factor. The results of this study may also provide 
some future directions for policy. For example, considering that the results of the study 
indicate that aggressive treatments may not be necessary in rGBM, policy changes may 
be made over time that could lead to substantial savings in the overall health care costs 
associated with the management of this disease. Therefore, the overall scope of this study 
– its research inquiry, methodology, and potential applicability – was contextualized 
within the conceptual framework of outcomes research in oncology. 
Nature of the Study 
This study was a retrospective cohort study based on quantitative data collected 
through retrospective chart reviews of adult patients diagnosed with GBM at select 
hospitals in Massachusetts. An observational study design, rather than an experimental 




association between exposure (i.e., IDH-1 mutation) and disease outcome (i.e., time to 
disease progression and overall survival) (Euser et al., 2009; Song & Chung, 2010). 
Retrospective cohort design was selected mainly for efficiency because a prospective 
cohort study would have been costly and time-consuming making it impractical for this 
dissertation project. Individual chart reviews for patients provided data on initial 
diagnosis and IDH-1 mutation status as well time to first recurrence, time to disease 
progression or subsequent recurrence, and death. Disease outcomes – time to recurrence 
from initial diagnosis, time to disease progression following first recurrence, and overall 
survival – was evaluated to determine whether IDH-1 mutation is a prognostic factor for 
adult GBM or rGBM patients. The Cox proportional-hazards model was used to assess 
the effect (hazard ratio) of IDH-1 mutation status on time to disease progression and 
survival. In addition, a Kaplan-Meir curve were generated to obtain the survival rate for 
patients with and without the IDH-1 mutation. A Cox regression analysis was also 
conducted to test the effects of other key covariates, including Karnofsky performance 
score (KPS), surgery at the time of recurrence, and O-6-methylguanine-DNA 
methyltransferase (MGMT) promoter methylation status on progression and survival. The 
prevalence of adult GBM was estimated based on the total number of adult brain cancers 
diagnosed at the select hospitals during the same period as the study. 
The study covered a duration of 12 years, from 2008 to 2020. To get an 
estimate of the incidence and prevalence of GBM, the medical records at select 
hospitals were searched for the total number of adult brain cancers and GBM patients 




prevalence of GBM was estimated as a proportion of overall adult brain cancers 
reported at the same centers during the specified time-period. 
Retrospective medical chart reviews of patients with GBM or rGBM were 
conducted to determine whether there is a significant difference in time to disease 
progression or median overall survival. The key data that were collected from the chart 
reviews included but not limited to: (a) patient demographics (e.g., age and gender), (b) 
date of initial diagnosis of GBM, (c) standard treatment received at disease onset, (d) 
IDH-1 phenotype and other genetic markers, (e) date of disease recurrence, (f) treatment 
following disease recurrence, (g) time to disease progression following first recurrence, 
and (h) date of death. Time to disease progression and overall survival for each patient 
was calculated based on the date of disease onset or diagnosis and the date of disease 
progression and death.   
Definitions 
Glioblastoma: A fast-growing central nervous system tumor that forms from glial 
(supportive) tissue of the brain and spinal cord (Ostrom et al., 2014; Ostrom et al., 2018). 
Recurrent glioblastoma: Glioblastoma typically returns or recurs after initial 
treatment that may include chemotherapy and surgical removal (Apolone, 2003; Li et al., 
2015).  
Overall survival: The duration or length of time that a patient is alive after initial 
date of diagnosis of the disease or the start of treatment (Iwamoto et al., 2009; Omuro & 
DeAngelis, 2013). In this study overall survival was assessed from the initial date of 




Median overall survival:  The duration or length of time that half of the patients in 
a group of patients are alive after initial date of diagnosis of disease or the start of 
treatment (Omuro & DeAngelis, 2013; Ostrom et al., 2014). 
Time to disease progression or progression free survival: Time to disease 
progression or progression free survival (PFS) is the duration or length of time after 
initial treatment when patient goes in remission and recurrence or relapse of cancer 
(Lamborn et al., 2008). In this study time to disease progression was considered as 
duration of time to first recurrence from initial treatment and duration of time to second 
recurrence from first recurrence.  
Resection: Surgery performed to remove the tumor mass, which can be total or 
partial resection depending on tumor location and access (Brown et al., 2016; Wilson et 
al., 2014).  
Prognostic factors: Patient characteristics or conditions that can provide some 
estimation about the chance of recovery or recurrence of a disease in patients (Audureau 
et al., 2018; Czapski et al., 2018; Goldman et al., 2018; Ostrom et al., 2018; Thakkar et 
al., 2014). In this study molecular markers that is, IDH-1 mutation status and MGMT 
promoter methylation status, and clinical factors like KPS, surgery for resection, and 
chemotherapy at progression were evaluated as prognostic factors.  
Assumptions 
The study was a retrospective cohort study based on quantitative data collected 
from electronic medical records (EMR) of adult patients diagnosed with GBM at select 




patient data in the EMR was collected and entered in a reliable and accurate manner, 
particularly for the key variables. This assumption was supported by the robust processes 
and standard operating procedures that each participating hospital have in place to ensure 
data integrity. It would not have been feasible for the researcher to conduct an 
independent audit of the data due to hospital policies, magnitude of the database, and 
patient privacy concerns under the Health Insurance Portability and Accountability Act 
(HIPAA) of 1996 (Rights (OCR), 2009). The other key assumption was the clinical 
assessment of recurrence and disease progression in GBM patients. While radiographic 
imaging was used as an objective measure to determine recurrence and progression of 
disease, the assessment was nonetheless made by a clinician. GBM patients are under the 
care of trained neurooncologists and such radiographical assessments are part of regular 
clinical practice, including oncology.   
Scope and Delimitations 
The study specifically evaluated the role of IDH-1 mutation in recurrent GBM 
because IDH-1 gene mutation has been extensively studied as a prognostic factor in 
GBM following initial diagnosis, but it has not been studied as much in rGBM (Amelot et 
al., 2015; Mandel et al., 2016; Ostrom et al., 2014; Ostrom et al., 2018; Thakkar et al., 
2014); therefore, only those GBM patients that have at least one confirmed diagnosis of 
recurrence following initial diagnosis were included in the study whereas GBM patients 
that do not have a confirmed diagnosis of recurrence were excluded from the study.  The 
study was designed as a retrospective cohort study based on quantitative data collected on 




Women’s Hospital and St. Vincent Hospital. These hospitals were selected to make the 
research feasible through ease of collaboration with oncologists at these centers and 
better access to EMR, which required the researcher to go through training at these 
hospitals. This approach would not have been possible if too many cancer centers had 
been selected, particularly ones in other states. 
The study was conceptualized within the research component of the outcomes 
research conceptual framework (Lee et al., 2000). It could be argued, however, that 
Determinants of Health model (WHO | The Determinants of Health, n.d.) could have 
been considered as the conceptual framework for this study. According to this model, the 
health of an individual is affected by a combination of multiple factors or determinants, 
and these determinants can be categorized into socioeconomic and physical environment, 
and the person’s characteristics and behaviors (WHO | The Determinants of Health, n.d.).  
Genetics and epigenetics, as a person’s individual characteristics, can play a role in the 
development of an illness, including cancer, and affect the response to treatment 
(Notterman & Mitchell, 2015). The model also entails, however, that multiple factors like 
diet, environment, and biology may impact the genetic and epigenetic profile of an 
individual (Mohammed et al., 2012). While the study investigated an epigenetic 
biomarker, IDH-1 mutation, as a “determinant of health” in rGBM patients, it was 
beyond the scope of this study to identify and account for all the factors that may lead to 
this epigenetic phenotype and reasonably address the key research questions. Therefore, 
outcomes research conceptual model was considered more appropriate for the scope of 




prediction rule (i.e., the prognostic value of IDH-1 in rGBM) using the outcomes (OS and 
PFS) within the research component of the conceptual framework (Lee et al., 2000). The 
results may provide future direction for the application component of the conceptual 
framework, including both clinical practice and policy aspects, but further research would 
be needed to validate the results of this study before such changes could be implemented.  
Since the data collected for the study was limited to two hospitals in 
Massachusetts and are not representative of the U.S. population, caution would need to be 
taken in the generalizability of the results and conclusions. However, there is no evidence 
to suggest that the pathophysiology and clinical course of GBM would be different across 
the United States, and the data collected for this study had an appropriate distribution of 
age, gender, and race/ethnicity variables consistent with the demographic data reported 
for GBM (Ostrom et al., 2018). Furthermore, EMR provides detailed clinical data that is 
relevant for outcomes research and is now increasingly used in clinical oncology and 
epidemiology studies (Lau et al., 2011). Therefore, the risk of external validity was 
considered minimal for this study.      
Limitations 
The key anticipated challenge and barrier for the study was access to GBM 
patient medical records for retrospective chart review; however, collaborations were 
established at select leading hospitals in Massachusetts, providing access to the data of 
close to 1500 GBM patients. As anticipated, there were enough GBM patients in the 
database to have a reasonable sample size for the study, the sample size was reduced once 




variable for the study, was applied. Clinical and molecular prognostic factors (e.g., age, 
Karnofsky performance status (KPS), surgical resection, chemotherapy at progression, 
and MGMT promoter methylation status) are considered key prognostic factors for 
survival in recurrent GBM (Archavlis et al., 2014; Audureau et al., 2018; Chaichana et 
al., 2013; Cloughesy et al., 2014; D’Amico et al., 2015; Ringel et al., 2016; Stupp et al., 
2012; Terasaki et al., 2007). Heterogeneity in these clinical and molecular prognostic 
factors in the study population was also anticipated. Considering that the prognostic value 
of the IDH-1 mutation for the rGBM patients in this study was determined by comparing 
outcomes like time to disease progression and mortality, the confounding variables were 
also factored in as covariates in the final data analysis. Cox regression analyses were 
conducted to address this limitation and to evaluate the effect of these confounding 
variables on the outcomes of interest. Analyses that matched the groups for these 
covariates were not conducted due to the small sample size. Inability to match cohorts for 
confounding variables is a general limitation and challenge that researchers face when 
conducting research in a rare disease space, like GBM. In rare diseases, the sample size is 
relatively small to begin with and patient heterogeneity makes it difficult to adjust for all 
confounding variables while still maintaining a reasonable sample size for statistical 
analysis.  
Cohort studies may also be susceptible to selection, information, and comparison 
bias (Euser et al., 2009). Inherent nature of the study that includes objective assessment 
of exposure and outcome adequately addresses these potential biases. In terms of 




interest (IDH-1) mutation was not dependent on the likelihood of them having the 
outcome of interest (disease progression and survival). Moreover, the diagnosis of GBM, 
both initial and recurring, was based on radiographic assessment and therefore it 
eliminated the selection bias due to differential referral or diagnosis (Euser et al., 2009). 
Similarly, information bias due to misclassification was unlikely since presence or 
absence of IDH-1 mutations is made by established laboratory diagnostic test.  
Significance 
This research study is significant from both epidemiological and patient care 
perspectives. The results of the study, including demographics, genetic features, clinical 
characteristics, prognoses, and outcomes, should provide insight to epidemiologists and 
health professionals regarding the similarities and potential differences of this disease in 
Massachusetts compared with national trends as reported in the literature. This study may 
inform how best to identify, diagnose, and treat rGBM patients at the selected centers in 
Massachusetts. 
The presumed role of the IDH-1 mutation as an overall prognostic factor upon 
initial diagnosis of GBM typically results in the selection of treatment modalities that are 
relatively aggressive, including a combination of resection, chemotherapy, and adjuvant 
therapy. In the absence of a clear understanding of the role of IDH-1 mutation status in 
recurrent GBM, there is a gap in knowledge about whether such an aggressive treatment 
approach in the recurrent setting would confer any added clinical or survival benefit to 
patients over standard of care. Considering that there are significant risks associated with 




clinical trials of investigational drugs, patients’ quality of life and an overall risk/benefit 
profile need to be considered when selecting the optimal treatment course. The results of 
this study are expected to contribute to positive social change by affecting both patient 
management and health care delivery in rGBM. The results of this study indicate that 
IDH-1 may not carry the same prognostic value after disease recurrence and treatment 
decision that are made based on this marker at initial diagnosis may not be relevant or 
accurate at disease recurrence. Considering that there are significant risks associated with 
aggressive treatments like combination of chemotherapies that are selected based on 
prognostic factors like IDH-1 mutation at initial diagnosis, the results of this study may 
mitigate unnecessary exposure of rGBM patients to the safety risks that are associated 
with such treatments. Similarly, if such treatments are not found necessary in the 
recurrent setting, then positive social change may be affected over time as it could lead to 
substantial savings in the overall health care costs associated with the management of this 
disease. 
Summary 
Glioblastoma is by far the most frequent malignant glioma. It is associated with a 
particularly aggressive course and a dismal prognosis (Ostrom et al., 2014). Extremely 
rapid cell infiltration is a key biological feature of glioblastoma: Tumor cells travel to 
other sites within the brain, which makes it very difficult to completely remove tumors 
through surgery (Olar & Aldape, 2014). Therefore, in conjunction with inadequate 
response to treatment, the recurrence rate is very high with GBM, resulting in poor 




referred to as recurrent GBM (rGBM), have a particularly poor prognosis, with a median 
OS (mOS) of 6 to 7 months. The OS in subjects who have failed temozolomide (TMZ) 
and bevacizumab, or equivalent salvage chemotherapy, is reported to be as short as 3 to 5 
months (Iwamoto et al., 2009; Omuro & DeAngelis, 2013). 
Isocitrate dehydrogenase-1 (IDH-1) mutation status is now used in the 
classification of gliomas, based on an understanding that IDH-1 mutant and wild-type 
gliomas have different underlying tumor biology and therefore need to be treated 
differently (Ostrom et al., 2018). Clinical data have showed benefits from the aggressive 
treatment of glioma patients with IDH-1 mutation, making upfront and initial treatment 
with RT and chemotherapy a standard of care for patients with IDH-1 mutant Grade II 
and III gliomas (Miller et al., 2017). However, the prognostic value of IDH-1 mutation in 
GBM remains controversial (Amelot et al., 2015; Mukasa et al., 2012; Zou et al., 2013) 
and limited studies have been conducted to evaluate the prognostic value of IDH-1 in 
rGBM (Mandel et al., 2016; Taal et al., 2014). Because the role of IDH-1 mutation in 
rGBM is not well understood, it is difficult to determine whether similar upfront 
aggressive treatment would confer any significant benefit to the patients, given the risks 
associated with RT and chemotherapy. Therefore, the purpose of this retrospective cohort 
study was to determine whether IDH-1 is a prognostic factor in rGBM. The Cox 
proportional-hazards model was used to assess the effect (hazard ratio) of IDH-1 
mutation status on time to disease progression and survival. A multivariate Cox 
proportional-hazard analysis was also conducted to evaluate if the correlation between 




of MGMT promoter methylation, age, KPS, surgery for resection, and chemotherapy at 
progression. It is anticipated that the results of this study will help GBM patients, and 
their treating physicians make more informed decisions about the most appropriate 
treatment regimen for managing the disease, particularly in the recurrent setting. Chapter 
2 provides additional background on the disease and the current understanding on the 
most relevant molecular and clinical prognostic factors in GBM/rGBM—it therefore 
provides the foundation for the study hypotheses and rationale for the selection of key 





Chapter 2: Literature Review 
Glioblastoma (GBM) is one of the most common types of malignant gliomas. It 
has an aggressive disease course and very poor prognosis. GBM may manifest at any age, 
but it typically affects adults at age 45-84 (Ostrom et al., 2018). Isocitrate dehydrogenase-
1 (IDH-1) gene mutation has been extensively studied as a prognostic factor in GBM 
following initial diagnosis, but it has not been thoroughly studied in recurrent GBM 
(rGBM). Even following initial diagnosis of GBM, the prognostic value of IDH-1 
mutation has been debated, as studies have demonstrated both weak and strong 
association between IDH-1 mutation and overall survival (Amelot et al., 2015; Mukasa et 
al., 2012; Zou et al., 2013). A few studies have examined the role of IDH-1 mutation in 
rGBM, but only in the clinical trial setting and with inconclusive results (Mandel et al., 
2016; Taal et al., 2014). 
The purpose of this study was to determine whether IDH-1 mutation is a 
prognostic factor in rGBM. In this retrospective cohort study, time to first recurrence 
from initial diagnosis and time to disease progression or death from first recurrence was 
evaluated in GBM patients with IDH-1 mutated and wild-type tumors.   
This literature review contextualizes the research study by focusing on topics and 
publications related to the construct and variables of interest. The key variable of interest 
for the research study is IDH-1 gene mutation status and its value as a prognostic factor 
in the overall survival of rGBM patients. Therefore, the review first focuses on molecular 
classification of GBM to highlight some important genetic markers, like IDH-1, that have 




review then focuses on the current knowledge base on prognostic factors, both clinical 
and molecular, in GBM and rGBM. These reviews of the molecular classification of the 
disease and prognostic factors provide the rationale for selecting IDH-1 mutation status 
as the key variable of the study, as well as the important molecular and clinical covariates 
that need to be considered when evaluating the association between IDH-1 mutation and 
overall survival in rGBM patients. Finally, a review of current treatment provides insight 
on how prognostic factors can inform treatment decisions. This review is relevant in the 
context of the social change that this study is anticipated to make in terms of the 
management of rGBM patients. There is a dearth of studies that have specifically focused 
on molecular and clinical prognostic factors in rGBM. However, the rationale for 
hypothesizing a role for various prognostic factors in rGBM can be derived from the 
existing research on GBM in general and rGBM in particular.  
Literature Search Strategy 
Pub-Med, Medline, Society of Neuro-Oncology publications, and Walden 
University Library were the primary sources for the literature search, which mainly 
focused on peer-reviewed journal articles. Key search terms included glioblastoma, 
recurrent glioblastoma, IDH mutation in glioblastoma, IDH mutation in recurrent 
glioblastoma, prognostic factors in glioblastoma, prognostic factors in recurrent 
glioblastoma, prognostic factors in glioblastoma meta-analysis, treatment of 
glioblastoma and recurrent glioblastoma, risk factors in glioblastoma, IDH mutation as 




glioblastoma, conceptual framework in cancer and oncology, and outcomes research in 
oncology.  
Considering the rapidly evolving research and knowledge about GBM, articles 
published over the last 3 to 5 years (2014 to 2020) were preferred for information on key 
variables of interest (e.g., IDH, molecular markers, and prognostic factors in GBM and 
rGBM). Earlier publications were considered for providing general background on GBM, 
foundational research, and conceptual framework. The search term meta-analysis was 
included for key variables like IDH mutation in GBM and prognostic factors in GBM.  
Conceptual Framework 
The aims and scope of the proposed study are congruent with the conceptual 
framework of outcomes research, particularly outcomes research in oncology, the goal of 
which is to improve medical practice to achieve better outcomes in patients (Lee et al., 
2000). The definition of outcomes research and what it encompasses has evolved since 
the mid-1960s, particularly in the field of oncology, with the realization that the 
emergence of tumors and tumorigenesis are complex phenomena involving genetic, 
epigenetic, metabolic, proteomic, and physiologic pathways (Kovvali, 2014). While the 
definition of outcomes research will continue to evolve, it is broadly understood as a field 
that describes, interprets, and predicts the influence of different factors on a final 
endpoint that may range from survival to patient satisfaction with care (Apolone, 2003).    
In 1966 Avidence Donabedian used the term “outcome” in the context of quality 
of medical care, with a focus on health services and care provided according to the 




healthcare costs and the focus of outcomes research shifted to health care costs (Lee et 
al., 2000). For example, in 1973 John Wennberg and Alan Gittelsohn highlighted 
different patterns and variations in care in terms of resource utilization and costs (Lee et 
al., 2000). In the 1990s, however, outcomes research began to include more specialties 
and subspecialties of clinical science in order to better understand the effectiveness of 
treatments and to enable clinicians to make more informed decisions (Lee et al., 2000). In 
the mid-1990s, a distinction between outcomes research and health services research 
began to emerge. Along with new technologies, therapeutic interventions, and clinical 
trials, the definition of clinical research also encompassed epidemiologic studies, 
outcomes research, and health services research (Nathan, 1998). Outcomes research 
began to address a broad range of questions and oncology-related endpoints, like overall 
survival (OS) and progression-free survival (PFS), which were studied utilizing 
administrative databases and cohort or case-control study designs (Lee et al., 2000).   
Lee et al. (2000) included a diagrammatic representation of the conceptual 











Figure 1  
Conceptual Framework for Outcomes Research  
 
 
Note: Lee et al. (2000, p. 200) (see Appendix for copyright permission). 
As indicated in Figure 1, Lee et al. (2000) suggested that clinical trials are not part 
of outcomes research, whereas quality of care, access, decision making, prediction rules, 
and effectiveness, along with outcome endpoints, are considered part of outcomes 
research. Lee et al. suggested that studies that use administrative databases are typically 
considered outcomes studies regardless of the questions they seek to address. Similarly, 
while endpoints like OS and PFS are also included in clinical trials, these endpoints are 
considered part of outcomes research when they are used in cohort studies with 




outcomes research has been liberally used and the nomenclature will continue to evolve, 
this study adopts their conclusion that “outcomes research is fundamentally concerned 
with improving the practice of medicine as applied to patients treated outside clinical 
trials” (Lee et al., 2000 p. 203) 
The view of Lee et al. (2006) seems to be corroborated by other researchers, who 
are increasingly arguing that outcomes research in oncology is more than health services 
research per se and that outcomes research itself requires an integrated multidisciplinary 
approach in order to understand the complexity of tumorigenesis and the factors that 
impact patient outcomes (Apolone, 2003; Fay et al., 2015; Kovvali, 2014; Melamed et 
al., 2017; Roberts et al., 2019). For example, drawing upon systems biology, Kovvali 
(2014) has proposed the term systems oncology, suggesting that the disease should be 
studied as a phenomenon from the perspective of multiple areas of research like 
molecular biology and immunology. Melamed et al. (2017) suggested that randomized 
clinical trials may not be feasible in gynecologic oncology, thus outcomes research based 
on well-designed observation studies can provide better guidance on clinical decisions. 
Similar views were expressed by Fay et al. (2015) with respect to GBM. They indicated 
that an integrated multidisciplinary research approach is needed to better understand this 
cancer and improve patient outcomes because GBM treatment practices have not 
significantly changed over the past 10 years.  
This study is aligned with the conceptual framework of outcomes research, 
particularly outcomes research in oncology as proposed by Lee et al. (2000) and 




Melamed et al., 2017; Roberts et al., 2019). The study’s research scope, methodology, 
and potential application fall within the parameters of research and applications of 
outcomes research that Lee et al. outlined and illustrated in the conceptual framework 
(see Figure 1). First, the purpose of this study was to determine whether IDH-1 mutation 
is a prognostic factor in rGBM by evaluating time to first recurrence from initial 
diagnosis and time to disease progression or death (overall survival) from first recurrence 
in GBM patients with IDH-1 mutated and wild-type tumors. This broadly fits the 
treatment options and prediction rules of the outcomes research framework. In GBM, 
IDH-1 mutation is an important prognostic factor that informs treatment options, and this 
study evaluated the role of this mutation in the recurrent setting. Second, the study 
utilized clinical outcomes, OS and PFS, that are suggested in the outcomes research 
framework. Third, the study was a retrospective cohort study and analyses were based on 
data obtained from electronic medical records (EMR) at select hospitals. EMR provides 
detailed clinical data that are relevant for outcomes research and is now increasingly used 
in clinical oncology and epidemiology studies (Lau et al., 2011). Moreover, Lee et al. 
(2006) suggested that studies that use administrative databases and study these endpoints 
are typically considered outcomes studies regardless of the questions they seek to 
address. Finally, the application aspect of the outcomes research conceptual framework 
suggests that the research should lead to clinical or policy decisions (Lee et al., 2000). 
The results of this study may inform clinical decisions in terms of treatment 
recommendations and clinical practice guidelines for the management of rGBM patients, 




mutation is not a prognostic factor in the recurrent setting and an aggressive treatment 
approach will most likely not confer any clinical or survival advantage over standard of 
care; therefore, the results of this study may mitigate the unnecessary exposure of patients 
to the risks associated with such procedures and treatments. Similarly, if such treatments 
are not found necessary in the recurrent setting, then policy changes may be made over 
time that could lead to substantial savings in the overall health care costs associated with 
the management of this disease. Therefore, the overall scope of this study, in terms of its 
research inquiry, methodology, and potential applicability, was contextualized within the 
conceptual framework of outcomes research in oncology.    
Literature Related to Key Variables 
Molecular Characterization of Glioblastoma 
A review of the molecular classification of GBM highlights some important 
genetic markers, like IDH-1, that have been identified in GBM and their potential role in 
the disease’s pathophysiology. Glioblastoma is morphologically or histologically divided 
into two identical subtypes: primary and secondary glioblastoma (Lieberman, 2017; Olar 
& Aldape, 2014). Primary glioblastoma occurs de novo without the presence of a 
precursor lesion and constitutes approximately 90% of GBM (Lieberman, 2017; Olar & 
Aldape, 2014). Secondary glioblastoma follows the progression of WHO Grades II or III 
with preexisting low-grade astrocytoma (Lieberman, 2017; Olar & Aldape, 2014).  
Recent advances in molecular neuropathology have shown that molecular 
characterization can be utilized to further classify glioblastomas that are histologically 




molecular alterations are complex, this genetic profiling has suggested there is prognostic 
value in these molecular variations and therefore a possible association with clinical 
outcomes of GBM. The following is a brief outline of the key genetic alterations in GBM 
that are considered clinically relevant (Lieberman, 2017; Olar & Aldape, 2014). 
Isocitrate Dehydrogenase (IDH) Mutation 
IDH has three isoforms, the most common of which includes mutation in IDH-1 
(IDH1-R132H) (Lieberman, 2017; Olar & Aldape, 2014). IDH mutations are noted in 
approximately 5% of primary GBM and 80% of secondary GBM (Lieberman, 2017; Olar 
& Aldape, 2014). IDH-1 mutation has been associated with better prognosis, particularly 
in high-grade gliomas (Lieberman, 2017; Olar & Aldape, 2014). In 2016, IDH mutation 
status was included in the WHO classification of GBM. Currently, GBM is classified as a 
WHO Grade IV tumor of the central nervous system and is divided into three subtypes 
based on histology and molecular parameters: IDH-wildtype, IDH-mutant, and not 
otherwise specified (Louis et al., 2016). The Cancer Genome Atlas (TCGA) researcher 
network has suggested that other genetic abnormalities may also be clinically relevant 
(Verhaak et al., 2010). 
Epidermal Growth Factor Receptor (EGFR) 
Upregulation of EGFR has been reported in 40-50% of glioblastomas, 
predominantly in primary glioblastomas but also in secondary glioblastomas (Lieberman, 
2017; Olar & Aldape, 2014). EGFR, including its mutant variants like EGFRvIII, has 
been shown to confer heterogeneity to tumor cells and upon activation leads to 




2017; Olar & Aldape, 2014). The effects of EGFR upregulation in GBM and rGBM are 
not clearly understood.  
O-6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation 
MGMT encodes a DNA repair protein that is responsible for removing alkyl 
groups that cause DNA damage (Olar & Aldape, 2014; Yang et al., 2015). The MGMT 
promoter contains CpG islands in the promoter region, and methylation of these CpG 
sites suppresses MGMT transcription (this is called MGMT silencing), thereby affecting 
DNA repair (Olar & Aldape, 2014; Yang et al., 2015). Based on this underlying 
molecular biology, methylation status of the MGMT promoter is associated with a more 
favorable response to alkylating chemotherapies, like temozolomide (TMZ). Over 50% of 
primary and secondary GBM patients have methylated MGMT promoter (Olar & Aldape, 
2014; Yang et al., 2015). While MGMT promoter methylation status is now considered a 
prognostic factor in patients with GBM, its prognostic value in rGBM is not fully 
established (Olar & Aldape, 2014; Yang et al., 2015).  
TP53 Mutation 
TP53 mutation has been reported in up to 30% of primary and 70% of secondary 
GBM patients (Thakkar et al., 2014). The prognostic value of TP53 mutation has not 
been established and studies conducted to evaluate it as a prognostic marker have been 
inconclusive (Thakkar et al., 2014).   
ATRX Mutation 
ATRX mutations result in genomic instability by causing alternative lengthening 




The ATRX is mutated in 57% of secondary GBM patients and tends to cluster with IDH-
1 and TP53 mutations (Thakkar et al., 2014). In astrocytic tumors, better prognosis has 
been reported for patients with ATRX mutation than in those that expressed unmutated 
ATRX and had IDH mutation (Thakkar et al., 2014).   
TERT Mutation 
TERT is important for growing cells and maintains telomeres. TERT mutations 
are the most frequently occurring genetic mutations in GBM and are significantly higher 
in primary GBM (Thakkar et al., 2014). While TERT mutations in GBM have been 
shown to correlate with EGFR upregulation, they have been shown to inversely correlate 
with TP53 and IDH mutations (Thakkar et al., 2014).  
Prognostic Factors 
This review of prognostic factors first covers GBM in general and then rGBM in 
particular. The intent is to provide background information that supports the investigation 
of IDH-1 mutation status as a potential prognostic factor in rGBM. The review of other 
clinical and molecular markers provides a rationale for the selection of appropriate 
covariates in the overall analysis.  
Prognostic Factors in GBM 
GBM patients have very poor prognosis: a 5-year survival after diagnosis is seen 
in less than 5% of patients (Ostrom et al., 2018; Thakkar et al., 2014). Research has 
focused on both clinical and molecular prognostic factors (Ostrom et al., 2018; Thakkar 
et al., 2014). Age at diagnosis, tumor location, performance status, and tumor resection 




markers discussed above (MGMT promoter methylation, IDH-1 mutation, EGFR 
upregulation, TP53 mutation, ATRX mutation, and TERT mutations) have been studied 
as potential molecular prognostic factors in GBM (Ostrom et al., 2018; Thakkar et al., 
2014).  
Clinical Prognostic Factors. Age 50 years is typically used as the cut-off from a 
prognostic value perspective, with a higher risk of death seen in patients over 70 years. 
The shorter survival rate for older GBM patients is most likely due to comorbidities and 
inability to tolerate the effects of the cancer itself and treatments like surgery and 
chemotherapy (Ostrom et al., 2018; Thakkar et al., 2014). In terms of tumor site, while 
the difference in the prognosis of cerebellar and supratentorial GBM is not clearly 
understood, frontal lobe tumors in supratentorial GBMs have better prognosis and 
survival outcomes (Ostrom et al., 2018; Thakkar et al., 2014).   
Surgical treatment includes complete macroscopic tumor removal or gross total 
resection (GTR) and subtotal resection (Czapski et al., 2018). While resection is an 
important treatment option in GBM, it does not offer a cure and is not completely 
effective due to the unclear boundary between tumor and healthy brain tissues and the 
infiltration of tumor cells into surrounding areas (Czapski et al., 2018). Even with this 
limitation, GTR has been shown to increase survival to up to 20 months in malignant 
gliomas, compared to 8.8 months with no GTR (Czapski et al., 2018). Lu et al. (2019) 
conducted a meta-analysis to look at the survival benefit of maximal resection for 
glioblastoma and reported that radiographic GTR was the most prognostic in terms of 




imaging, ultrasonography, and tumor staining are now utilized to better define the tumor 
boundaries and maximize resection (Czapski et al., 2018). Recent studies, however, have 
highlighted the timing of resection and its association with PFS and OS in GBM 
(Goldman et al., 2018; Y.-H. Zhao et al., 2019). For example, a lower risk of death (HR: 
0.62) was noted with repeat resection without taking the timing of resection into account, 
but a higher risk of death was noted (HR: 2.19) after adjustment for the timing of 
resection (Goldman et al., 2018). An association has also been noted between tumor 
resection and IDH mutation, as patients with IDH-mutated tumors showed better 
prognosis following maximal tumor resection (Czapski et al., 2018).  
Molecular Markers as Prognostic Factors. Several molecular prognostic 
markers have been investigated in GBM and their interactions are complex (Xavier-
Magalhães et al., 2013). The prior section provided a brief outline of the key molecular 
markers in GBM. This subsection focuses on the two markers, MGMT promoter 
methylation and IDH-1 mutation, that are considered the most promising in terms of their 
prognostic value and that have been extensively studied for this purpose.  
MGMT Promoter Methylation. As discussed earlier, silencing of MGMT by 
promoter methylation suppresses MGMT transcription (MGMT silencing), thereby 
affecting DNA repair (Olar & Aldape, 2014; Yang et al., 2015). Two landmark studies 
showed that MGMT silencing leads to increased sensitivity to chemotherapy with 
temozolomide, thereby improving patient survival (Hegi et al., 2005; Stupp et al., 2009). 
Hegi et al. (2005) showed that mOS in patients with methylated MGMT was 21.7 




Stupp et al. (2009), longer survival was noted in patients with MGMT promoter 
methylation. These patients also responded better to a combination of radiotherapy (RT) 
and chemotherapy. These two studies provided initial evidence for MGMT promoter 
methylation as a prognostic molecular marker in GBM.  
Several studies have been conducted over the last 10 years to further evaluate the 
role of MGMT promoter methylation as a prognostic factor in GBM. This body of work 
has been captured in three meta-analyses (Olson et al., 2011; H. Zhao et al., 2016; Y.-H. 
Zhao et al., 2018). Olson et al. (2011) was based on 2018 patients in 20 different studies 
and showed a high association between MGMT promoter methylation and overall 
survival in patients receiving chemotherapy (Olson, 2011). Similarly, both H. Zhao et al. 
(2016) and Y.-H. Zhou et al. (2018) indicated that MGMT promoter methylation was 
associated with improved PFS and OS in GBM patients. For example, Y.-H. Zhao et al. 
included 64 studies and evaluated the association between OS and MGMT promoter 
methylation in GBM patients. The meta-analysis showed that the OS was significantly 
better (HR = 0.52) in patients with methylated MGMT promoter than in patients with 
unmethylated status (Y.-H. Zhao et al., 2018). Overall, these studies suggest a prognostic 
value for MGMT promoter methylation in GBM patients (Olson et al., 2011; H. Zhao et 
al., 2016; Y.-H. Zhao et al., 2018). There are, however, other studies that did not show a 
statistical significance between MGMT promoter methylation and survival (Costa et al., 
2010; van den Bent et al., 2009; Xavier-Magalhães et al., 2013). For example, Costa et al. 




noted in MGMT promoter methylation and PFS and OS, it was not statistically 
significant (Costa et al., 2010).  
IDH Mutations. IDH-1, IDH-2, and IDH-3 are three different isoforms of IDH. 
Mutations in IDH-1 and IDH-2 have been identified in both hematologic and solid 
tumors, including low-grade gliomas and secondary glioblastomas (Golub et al., 2019; 
Kaminska et al., 2019; Tommasini-Ghelfi et al., 2019). IDH-1 mutation is the most 
common (> 95%) type of IDH mutation, while an association between tumors and IDH-3 
mutation has not been reported (Deng et al., 2018; Golub et al., 2019; Kaminska et al., 
2019). IDH-1 and -2 are nicotinamide adenine dinucleotide phosphate (NADP+)-
dependent enzymes that are involved in the decarboxylation of isocitrate to α-
ketoglutarate (α-KG) and protect cells and DNA from being damaged by reactive oxygen 
species (ROS) and other oxidative stress (Kaminska et al., 2019). The mutated IDH 
enzyme not only loses the aforementioned catalytic function, but also leads to reduction 
of α-KG to 2-hydroxyglutarate (2-HG), which is an oncometabolite that causes cancer 
(Kaminska et al., 2019).  
Approximately 90% of GBM cases are IDH-wild type and are known as primary 
GBM, while the 10% of cases that carry IDH mutation, predominantly IDH-1 mutation, 
are considered secondary GBM (Tateishi et al., 2017; Tommasini-Ghelfi et al., 2019). 
Over the years, many studies have established IDH-1 mutation as a favorable prognostic 
factor for both PFS and OS in adult GBM (Chen et al., 2016; Cheng et al., 2013; Juratli et 
al., 2012; Kaminska et al., 2019; Nobusawa et al., 2009; Sun et al., 2013; Tateishi et al., 




meta-analysis that included randomized controlled trials and prospective and 
retrospective studies of patients with GBM; it used PFS and OS to evaluate the 
association between IDH mutation and prognosis. The pooled hazard ratios of 0.322 
(95% CI 0.24200.455, P < .001) and 0.358 (95% CI 0.264-0.487, P < .001) indicated that 
IDH mutation was associated with PFS and OS, respectively (Chen, 2016). Similarly, Xi 
et al. (2015) performed a meta-analysis of 55 observational studies, including 9,487 
glioma patients, and found that patients with IDH mutation had a better prognosis in 
terms of both PFS (HR = 0.42, 95% CI: 0.35-0.51; P < .001) and OS (HR = 0.39, 95%CI: 
0.34-0.45; P < .001). An earlier meta-analysis by Cheng et al. (2013) that included nine-
studies, with a total of 1,669 GBM patients, also confirmed that IDH-1 mutation was 
associated with improved survival in patients with GBM (HR = 0.45, 95%CI 0.29-0.69, P 
< .001). Some studies, however, do not support an association between IDH-1 mutation 
and long-term survival in GBM and indicate that IDH mutation is a weak predictor of 
overall survival in GBM (Amelot et al., 2015; Mukasa et al., 2012). For example, Amelot 
et al. (2015) conducted a retrospective analysis of 207 GBM patients and reported that 
the rate of IDH mutation was not statistically significant between non-long-term survivor 
and long-term survivor groups (1.16% versus 5.9%, p = .14).  
Some underlying mechanisms by which IDH-1 mutation may confer survival 
benefit to GBM patients include: (a) while the IDH-1 mutation plays a role in causing 
cancer, it also makes cells carrying this mutation susceptible to ROS-based 
chemotherapies; (b) tumors with IDH-1 mutation seem to be located in less risky parts of 




resection, which plays an important role in survival; and (c) patients with IDH-1 mutated 
tumors typically display better neurocognitive function and overall performance score 
(Tateishi et al., 2017).   
Prognostic Factors in Recurrent GBM 
Identifying factors that can predict survival outcomes following recurrence of 
GBM is of interest because these factors can inform treatment modalities for such 
patients. Age, Karnofsky performance status (KPS), surgical resection, and chemotherapy 
at progression have been identified as key clinical prognostic factors for survival in 
recurrent GBM (Archavlis et al., 2014; Audureau et al., 2018; Chaichana et al., 2013; 
Cloughesy et al., 2014; D’Amico et al., 2015; Ringel et al., 2016; Stupp et al., 2012; 
Terasaki et al., 2007). However, the complexity of disease pathophysiology and 
interactions between molecular and clinical markers of prognosis make it challenging to 
conclusively determine the most appropriate prognostic factors in GBM, including 
rGBM. For example, while Audureau et al. (2018), in their study of 777 adult patients 
with recurrent glioblastoma, identified surgical resection at recurrence as an independent 
predictor of long-term survival (HR, 0.57; 95% CI 0.44-0.73; p < .001), their findings are 
confounded by the exclusion of IDH mutation status and MGMT promoter methylation 
status, which are independent predictors of overall survival, at least in GBM. Moreover, 
while several studies have established surgical resection as a predictor of overall survival 
in rGBM (Audureau et al., 2018; Chaichana et al., 2013; D’Amico et al., 2015), other 
studies have suggested that surgery at progression may not be a prognostic marker for 




independent data sets of 511 and 247 rGBM patients and found no statistically significant 
difference in 6-month PFS or OS between patients with and without surgery at 
progression (Clarke et al., 2011). Despite these discrepancies, age, KPS, surgical 
resection, and chemotherapy at progression should be considered as important prognostic 
factors in rGBM and factored in as covariates when investigating any other specific 
prognostic factors.  
Molecular markers like IDH-1 gene mutation have been extensively studied as 
prognostic factors in GBM, but not in the recurrent setting. Even following initial 
diagnosis of GBM, the prognostic value of IDH-1 mutation is being debated in view of 
studies that have demonstrated both weak and strong association between IDH-1 
mutation and overall survival (Amelot et al., 2015; Mukasa et al., 2012). A few studies 
have examined the role of IDH-1 mutation in rGBM, but only in the clinical trial setting 
and the results were not conclusive (Mandel et al., 2016; Taal et al., 2014). These studies 
suggested that patients with an IDH-1 mutated tumor show an improved trend in overall 
survival at first recurrence. However, IDH-1 mutation did not result in prolonged PFS or 
OS compared to IDH-1 wild-type tumors in recurrent GBM trials (Mandel et al., 2016). 
Moreover, studies conducted by Mandel (2016) and Taal (2014) included a total of only 
10 patients (five patients in each study) with IDH-1 mutation. The authors indicated that 
the results of these studies must be interpreted with caution, considering the very small 
sample size, and suggested additional studies to better understand the role of IDH-1 




Current Therapies and Unmet Medical Need 
Newly diagnosed GBM subjects have a median overall survival (mOS) of 12 to 
15 months and a 2-year OS rate of up to 27% (Omuro & DeAngelis, 2013). Subjects who 
have experienced multiple recurrences have a poor prognosis, with an mOS of 6 to 7 
months; OS in subjects who have failed TMZ and bevacizumab, or equivalent salvage 
chemotherapy, is reported to be as short as 3 to 5 months (Iwamoto et al., 2009; Omuro & 
DeAngelis, 2013). The poor median OS rates in rGBM, resulting from the available 
treatment options not extending the subjects’ OS beyond 6 or 7 months, highlights the 
seriousness of recurrent or progressive GBM as well as the unmet medical need in 
treating this disease. 
The current FDA-approved therapies – bevacizumab, carmustine wafer, 
NovoTTF-100A, and lomustine – are marginally effective in extending OS in subjects 
with recurrent or progressive GBM (Davis, 2016). Despite the scientific advances in 
immunotherapies and monoclonal antibodies, a new standard of care for GBM has not 
been established in over 10 years. TMZ following RT is still the standard of care and it 
was established in 2005 following a Phase 3 trial that was led by Roger Stupp and 
sponsored by the European Organization for Research and Treatment of Cancer and the 
NCI - Clinical Trials Group (Davis, 2016; Stupp et al., 2009). The lack of standard 
salvage therapies has prompted the use of unsatisfactory treatment options, such as 
nitrosoureas, temozolomide re-challenge, and other targeted agents (Davis, 2016). In 
addition to surgical resection and approved therapies, a better understanding of tumor 




in disease pathophysiology has led to the initiation of clinical trials with various immune 
modulators, including monoclonal antibodies, vaccines, PD-1/PDL-1 checkpoint 
inhibitors, and DNA methyltransferase inhibitors (Artene et al., 2018; Chin et al., 2018; 
Jain, 2018; Paolillo et al., 2018; Zhang et al., 2019). These therapies, if proven effective 
and safe either as monotherapies or in combination, can provide additional treatment 
options for GBM patients.  
Summary of Research Approach in Literature 
GBM is considered to be of the most aggressive and untreatable forms of cancer 
(Paolillo et al., 2018). The topics of research in GBM aimed at understanding the 
pathophysiology of the disease and meeting the needs of patients through more effective 
treatments are expansive and rapidly evolving. On the one hand, researchers are focusing 
on molecular, genetic, epigenetic, and immunological markers in GBM, not only to better 
classify the disease but also to evaluate the prognostic value of these markers in terms of 
disease outcomes. On the other hand, researchers are also evaluating the role of clinical 
prognostic factors, such as age at diagnosis, tumor site, surgical resection, and its timing, 
KPS, and chemotherapeutic regimens, in the disease outcome. However, there are 
complex interactions between these molecular and clinical prognostic factors and 
researchers are aware that they need to adjust for other potential prognostic factors, both 
molecular and clinical, when evaluating the role of any specific factor for its prognostic 
value. This study took similar considerations into account in its design.   
Apart from some prospective clinical trials conducted for novel therapies 




pathophysiology, most of the research conducted in this space has been retrospective. 
Because these retrospective studies are typically single- or limited-center studies, similar 
patient molecular and clinical information is available to make reasonable comparisons 
for the variables of interest. Furthermore, the number of such retrospective studies 
conducted over the years has created a database that is adequate for more in-depth 
analysis, as indicated by meta-analyses that have evaluated the prognostic value of 
MGMT promoter methylation status, IDH mutation status, and surgical resection for the 
long-term survival of GBM patients. However, there are some general limitations to 
conducting GBM research, which are further accentuated in retrospective studies 
conducted at limited centers. First, GBM is a rare disease with just over 100,000 patients 
in the United States; this affects the sample size and design of the studies conducted. 
Second, the GBM patient population is very heterogenous in terms of the genetic, 
epigenetic, and immunological markers that they express and the treatment modalities 
that they receive in the course of their disease (e.g., surgical resections and the timings of 
these resections, chemotherapies, and immunotherapies). This overall heterogeneity, 
along with the rareness of the disease and the small sample size, makes it difficult to 
completely match the groups in a comparative study on the variable of interest.  
Summary and Conclusions 
The body of knowledge on rGBM, including studies evaluating its prognostic 
factors, is less extensive than on GBM overall. While it is reasonable to draw inferences 
from the results of studies that evaluated prognostic factors for GBM, the prognostic 




as well to inform the most suitable treatment course for GBM patients following 
recurrence. This literature review has indicated that for rGBM researchers have focused 
more on clinical prognostic factors like tumor location and timing of surgical resection 
than on molecular prognostic factors. A few studies have explored the prognostic value of 
molecular markers like IDH mutation in rGBM, but the sample size was too small to 
draw any reasonable conclusions. Considering that there is still some debate about the 
prognostic value of factors like MGMT promoter methylation and IDH mutation even in 
GBM, further studies are warranted that specifically evaluate the prognostic value of such 
factors in rGBM. 
The focus of this research study was to evaluate the prognostic value of IDH-1 
mutation status in rGBM. Because GBM is not curable, all patients relapse: disease 
recurs at some point following remission after initial treatment. While the overall 
knowledge of clinical and molecular prognostic factors in GBM also informs 
treatment-modalities selected for patients at recurrence, a better understanding of the 
relevance of these prognostic factors in the recurrent setting may provide further insight 
into treatment decisions for rGBM patients. For example, understanding the role of IDH-
1 in rGBM is relevant because over the years clinical data has shown a benefit from the 
aggressive treatment of glioma patients with IDH-1 mutation, thereby making upfront 
and initial treatment with RT and chemotherapy a standard of care for patients with IDH-
1 mutant gliomas (Miller et al., 2017). Because the role of IDH-1 mutation in rGBM is 




recurrence will confer any significant benefit to the patients, given the potential risks 
associated with RT and chemotherapy.   
Other relevant molecular and clinical prognostic factors need to be considered as 
covariates in investigating the prognostic value of IDH-1 in rGBM. This literature review 
suggests that MGMT promoter methylation (molecular marker), age, KPS, surgery for 
resection, and chemotherapy at progression (clinical factors) would be important 
covariates when comparing the PFS and OS of rGBM patients with and without IDH-1 
mutation.   
Consistent with other studies conducted to determine the association between 
prognostic factors and clinical outcomes like PFS and OS, this study was a retrospective 
cohort study based on quantitative data collected through retrospective chart reviews of 
adult patients diagnosed with GBM at select hospitals in Massachusetts. Individual chart 
reviews for patients provided data on initial diagnosis and IDH-1 mutation status as well 
time to first recurrence, time to disease progression or subsequent recurrence, and death. 
Disease outcomes – time to recurrence from initial diagnosis, time to disease progression 
following first recurrence, and overall survival – was evaluated to determine whether 
IDH-1 mutation is a prognostic factor for adult rGBM patients. The Cox proportional-
hazard model was used to assess the effect (hazard ratio) of IDH-1 mutation status on 
time to disease progression and survival. In addition, a Kaplan-Meir curves were 
generated to obtain survival rate for patients with and without IDH-1 mutation. Cox 




MGMT promoter methylation, age, KPS, surgery for resection, and chemotherapy at 





Chapter 3: Research Method 
Introduction 
The purpose of this study was to determine whether isocitrate dehydrogenase-1 
(IDH-1) mutation is a prognostic factor in recurrent glioblastoma (rGBM) considering 
other molecular and clinical prognostic factors as covariates. In a retrospective cohort 
study, time to first recurrence from initial diagnosis and time to disease progression or 
death from first recurrence was evaluated in GBM patients with IDH-1 mutated and wild-
type tumors. The effect of key variables (i.e., O6-methylguanine-DNA methyl-transferase 
(MGMT) promoter methylation, age, Karnofsky Performance Score (KPS), surgery for 
resection, and chemotherapy at progression) on correlation between IDH-1 mutation 
status and disease progression and survival was evaluated. The study also determined the 
overall prevalence of GBM as a type of nervous system cancers reported at select centers 
in Massachusetts. 
This chapter provides an overview of the research design and rationale to address 
specific research questions pertaining to potential prognostic role of IDH-1 mutation in 
disease progression and overall survival of rGBM patients as well the effects of other 
covariates on prognostic effect of IDH-1 mutation. The population and sampling sections 
describe the population of GBM patients that was included in the study and the inclusion 
criteria that was used to include subject specific data in the overall evaluable sample from 
the retrospective cohort. The data analysis plan section describes how each research 
question was addressed based on the key study variables utilizing appropriate statistical 




obtained through Walden University. Chapter also covers aspects of external and internal 
validity based on the overall scope of the study and its design and limitations. A brief 
overview of ethical considerations is included before the overall summary of this chapter.    
Research Design and Rationale 
Study Variables 
In a retrospective cohort study design, relevant data on GBM patients was 
collected at two selected Massachusetts hospitals (i.e., Brigham and Women’s and St. 
Vincent Hospitals). Table 1 outlines the patient-level independent and dependent 
variables that were selected to address specific research questions. The status of IDH-1 
mutation was the key independent variable and was categorized as a nominal variable. 
Key dependent variables were time-to-disease progression and survival. These dependent 
variables were categorized as interval variables (i.e., number of days) and were measured 
from initial diagnosis of GBM in each subject as well from first and/or subsequent 
recurrences in the same subject. In addition to demographic information, independent 
variables included key covariates selected for the study including MGMT promoter 








Variable Coding Description Level of Measurement 
Independent Variables (Exposure Variable) 
IDH-1 mutation status Yes = 1; No = 2  Nominal 
Gender Female = 1; Male = 2 Nominal 
Age > 18 and <55 = 1; 56-65 = 
2; 
66-75 = 3; >76 = 4 
Nominal  
Ethnicity Black = 1; White = 2; 
Hispanic = 3; Asian = 3 
Other/Unknown = 4 
Nominal 
Hospital  BWH* = 1; SVH** = 2 Nominal 
MGMT promoter 
methylation 
Yes = 1; No = 2 




>70 = 1; <70 =2  
Missing data = 3 
Nominal 
Surgery for resection Yes = 1; No = 2 Nominal 
Chemotherapy at 
recurrence 
Yes = 1; No = 2 Nominal 
Dependent Variables (Outcome Variable) 
Time to disease 
progression or first 
recurrence from initial 
diagnosis 




Variable Coding Description Level of Measurement 
Time to subsequent 
recurrence from first 
recurrence 
Number of days Interval 
Time to death from initial 
diagnosis 
Number of days Interval 
Time to death from first 
recurrence 
Number of days Interval 
*BWH = Brigham and Women’s Hospital. 
**SVH = St. Vincent Hospital. 
 The two hospitals included in this study represented two major centers, one each 
in the Eastern (BWH) and Western (SVH) part of Massachusetts. There are other 
hospitals in the region that refer GBM patients to BWH. The retrospective analysis 
timeframe for this study included a period of 12 years from January 2008 to 2020.  
Study Design 
 This study was a retrospective cohort study based on quantitative data collected 
through retrospective chart reviews of adult patients diagnosed with GBM at select 
hospitals in Massachusetts. An observational study design, rather than an experimental 
design, was selected considering the scope of the study that aimed to evaluate the 
association between exposure (i.e., IDH-1 mutation) and disease outcome (i.e., time to 
disease progression or progression free survival and survival) (Euser et al., 2009; Song & 






Exposure and Cohorts 
IDH-1 gene mutation in tumors of GBM patients was considered as the exposure 
of interest for the purposes of this study; therefore, the two cohorts were defined based on 
this exposure status that is, GBM patients that had IDH-1 mutation and GBM patients 
without IDH-1 mutation or wild-type IDH-1 gene. In GBM, testing for IDH-1 mutation 
status is done utilizing sensitive diagnostic tests at the time of the initial diagnosis of the 
disease and the result of this testing is included in the medical records along with other 
clinical and diagnostic assessments conducted as part of the initial diagnosis. In this 
study, the date of exposure (IDH-1 mutation status) for each patient in each cohort was 
the same as the date of their initial diagnosis of GBM as this testing was conducted per 
the standard practices as part of the initial diagnosis and the information was available 
during the initial chart review; therefore, for the purposes of this study the exposure in 
each patient in each cohort occurred before the outcomes described below. 
Study Outcomes 
Time to disease progression or progression free survival (PFS) and survival were 
the two main outcomes selected for this study. PFS was considered as the duration of 
time from initial diagnosis and treatment of disease to first recurrence and duration of 
time from first recurrence to subsequent recurrence or disease progression. Survival was 
considered as either the duration of time from initial diagnosis of the disease to death or 
duration of time from first recurrence of disease to death. In this study, time in days was 
calculated to determine PFS and survival in patients with and without mutated IDH-1 




included a date, along with a documented imaging evidence, of disease recurrence that 
allowed to determine the duration of time from initial diagnosis to first and subsequent 
recurrences. Similarly, the date of death was also recorded in the medical records that 
allowed to determine the survival duration from initial diagnosis and from first disease 
recurrence. As noted above, the date of the IDH-1 mutation status (exposure) was 
considered the same as the date of initial diagnosis as this information was available in 
the records for each patient at initial diagnosis. The events of disease progression and 
death, that respectively determined the outcomes of PFS and survival, happened after the 
initial diagnosis of disease and determination of IDH-1 mutation status; therefore, the 
exposure in each patient in each cohort occurred before the selected study outcomes. 
Individual chart reviews for patients provided data on initial diagnosis and IDH-1 
mutation status as well time to first recurrence, time to disease progression or subsequent 
recurrence, and death. Disease outcomes – time to recurrence from initial diagnosis, time 
to disease progression following first recurrence, and overall survival – were evaluated to 
determine whether IDH-1 mutation is a prognostic factor for adult GBM and rGBM 
patients. Retrospective cohort design was selected mainly for efficiency because a 
prospective cohort study would have been costly and time-consuming making it 
impractical for this dissertation project. Moreover, the proposed study was aligned with 
the conceptual framework of outcomes research, particularly outcomes research in 
oncology that has been generally adopted by researchers (Apolone, 2003; Fay et al., 
2015; Kovvali, 2014; Lee et al., 2000; Melamed et al., 2017; Roberts et al., 2019). 




like overall survival (OS) and progression-free survival (PFS), which are now being 
studied utilizing administrative databases and cohort or case-control study designs 
(Apolone, 2003; Fay et al., 2015; Kovvali, 2014; Lee et al., 2000). The study utilized 
clinical outcomes, OS and PFS, that are suggested in the outcomes research framework 
and were based on data obtained from electronic medical records (EMR) at select 
hospitals. EMR provides detailed clinical data that are relevant for outcomes research and 




The target population consisted of subjects with confirmed diagnosis of GBM in 
the EMR database of the two hospitals in Massachusetts. Some subjects obtained their 
initial diagnosis of GBM at other hospitals in the region and were referred to these 
hospitals for treatment. The databases were searched through a Research Patient Data 
Repository (RPDR) query using the International Classification of Disease-10 (ICD-10) 
code. Since GBM or rGBM does not have a specific ICD-10 code, initial search was 
conducted using the ICD-10 code C71 for “malignant neoplasm of the brain.” As 
anticipated the search based on ICD-10 code C71 resulted in approximately 1200-1500 
cases that included all neoplasms of the brain. It was not feasible to review individual 
patient records of all these cases to identify patients that would qualify for evaluable 
population (i.e., subjects included in the analysis plan) to determine the prognostic value 




outlined below in sampling and sampling procedure was used instead to identify 
evaluable study population based on the key variables of the study that is, IDH-1 
mutation status and GBM patients with documented recurrence of their disease.  
Sampling and Sampling Procedures 
This study was based on secondary analysis through retrospective chart review of 
quantitative data collected on adult subjects with GBM at select hospitals in 
Massachusetts. Since it was not possible to review the 1200 to 1500 cases that resulted 
from suing the ICD-10 code C71 for “malignant neoplasm of the brain”, the database 
search strategy was revised to identify relevant cases based on the key variables of the 
study that is, IDH-1 mutation status and GBM patients with documented recurrence of 
their disease. The database was first queried for all patients who had been tested for IDH-
1 mutation and this search yielded a total of 588 cases. Since IDH-1 mutation can be of 
interest in a variety of oncologic conditions (e.g., myeloid leukemia, breast cancer, and 
lung cancer) (Bledea et al., 2019; Hodges et al., 2013), the ICD-10 code C71 for 
neoplasm of the brain was then applied to these 588 cases to further narrow the cases to 
relevant study population and this step reduced the sample size to 405 cases. In the final 
step, individual patient records for all 405 cases were reviewed and per the 
inclusion/exclusion criteria those patients that had non-glioblastoma tumors, or did not 
have confirmed diagnosis of GBM through radiographic imaging, or GBM patients with 
no documented evidence of recurrence were excluded from the final dataset. This 
strategy resulted in a final sample size of 177 cases, whose charts were then reviewed in 




questions. Each subject’s protected health information, except for demographic 
information, was de-identified and all relevant data was entered on an Excel spreadsheet 
and cross-checked against the EMR generated output for accuracy. These data were then 
uploaded from the Excel spreadsheet into SPSS v25 for analysis.  
An a priori analysis conducted using G*Power3 indicated that a sample size of 
108 subjects was needed to detect a small effect size (d = .15) at an expected power of .90 
and an alpha of .05 (Faul et al., 2007). The sample size was also estimated using the 
method proposed by Hsieh and Lavori (2000) that provides a conservative sample size 
estimation specifically for Cox proportional hazard regression model (Hsieh & Lavori, 
2000). Although the inclusion criteria restricting the study sample to only rGBM patients 
with known IDH-1 mutation status narrowed the overall study population, the final 
sample size (177 cases) still exceeded the sample size of 108 that was estimated a priori 
using G*Power3 (Faul et al., 2007). 
Data Collection  
The study was designed as a retrospective cohort study. A major step in the data 
collection process was the selection of participating hospitals to ensure that enough 
relevant and reliable data was available for GBM patients to address the research 
questions and the relative ease with which this data could be accessed for the study. 
Initial assessment was done by interviewing neuro oncologists within my professional 
network to determine the number of GBM cases seen or referred to select hospitals in the 
areas, the availability of medical records for these patients, interest in collaboration on 




collaborating researchers. Brigham and Women’s Hospital (BWH) and St. Vincent 
Hospital (SVH) were selected for this study because it was anticipated that there were 
approximately 1500 hundred subjects with neoplasms of the brain in the combined 
databases that could provide required sample size per the inclusion/exclusion criteria of 
the study particularly key variables of the study that is, patients with known IDH-1 
mutation status and document evidence of recurrent GBM. Furthermore, both hospitals 
have a robust EMR system in place for patient medical records that could be searched 
and retrieved for required information. BWH and SVH are key hospitals, respectively, in 
the Eastern and Western part of Massachusetts and GBM patients from other hospitals in 
the region are also referred to BWH. Dr. Timothy Smith, Director, Computational 
Neuroscience Outcomes Center and Assistant Professor of Neurosurgery, Brigham and 
Women’s Hospital and Harvard Medical School and Dr. Daniyal Siddiqui, Chief, 
Division of Hematology and Medical Oncology, St. Vincent Hospital agreed to 
collaborate on the study. A brief outline of the research study was submitted to both 
collaborating oncologists and these clinicians facilitated institutional/IRB approval.  
Ability to access patient level data, as a researcher not employed at the hospital, 
was also an important factor in selecting BWH and SVH as participating hospitals in this 
study. The EMR data at BWH was accessed as part of an already approved broader GBM 
research protocol under the supervision of collaborating and principal investigator, Dr. 
Timothy Smith. Dr. Smith included me in his research team, and I completed all BWH 
required training prior to the start of data collection. Similarly, Dr. Daniyal Siddiqui 




collaborating researcher. Once appropriate approvals from Walden University were 
obtained, including IRB approval, data collection step was initiated for the study. The 
BWH and SVH’s institution policy allowed me to view the EMR, but I was not able to 
query the data since only employed medical personnel are given EMR log-in information. 
I created the data query based on the inclusion criteria and study variables of interest and 
queried the EMR for the required datasets in collaboration with and under the supervision 
of Dr. Smith and Dr. Siddiqui’s designated residents on the team. Confidentiality of the 
retrieved EMR data was maintained by ensuring that the data were not disclosed to any 
unauthorized user at any time and any data that were not properly de-identified was held 
with Drs. Smith and Siddiqui at the hospital with limited access by only authorized 
individuals on their team. Once the data were retrieved, each subject’s protected private 
health information, except for demographic information, was de-identified. The de-
identified data were then entered on an Excel spreadsheet and cross-checked against the 
EMR generated output for accuracy. The de-identified data was downloaded from the 
Excel spreadsheet into SPSS v25 for analysis. 
Electronic medical records provide detailed clinical data that is relevant for 
outcomes research and is now increasingly used in clinical oncology and epidemiology 
studies (Lau et al., 2011). It was assumed for purposes of this study that patient data in 
the EMR was collected and entered in a reliable and accurate manner since both 
participating hospitals follow robust processes and standard operating procedures to 
ensure data integrity. It was not feasible to conduct an independent audit of the data due 




Health Insurance Portability and Accountability Act (HIPAA) of 1996 (Rights (OCR), 
2009) . Similarly, GBM patients are under the care of trained neuro oncologists; 
therefore, it was assumed that the medical information they entered about their patients in 
the EMR was accurate because of their extensive training in the medical practice of neuro 
oncology.   
Data Analysis Plan 
Data analysis was conducted using the SPSS v25 obtained through Walden 
University. Data in SPSS was directly uploaded from an Excel spreadsheet and manual 
check was performed to ensure accuracy of data transfer. The data analysis addressed the 
following study specific research questions and hypothesis. These research questions 
along with key variables, their level of measurement, and statistical methods that were 
used to address each question are outlined in Table 2. 
RQ1: Is there a significant difference in time to disease progression and overall 
survival after first recurrence between rGBM patients with IDH-1 mutation and those 
without IDH-1 mutation? 
H01: Based on IDH-1 mutation status, there is no statistically significant 
difference in the time to disease progression and/or overall survival of rGBM patients. 
H11: Based on IDH-1 mutation status, there is a statistically significant difference 
in the time to disease progression and/or overall survival of rGBM patients. 
RQ2: Is the correlation between IDH-1 mutation status and disease progression 
and survival after first recurrence affected by the covariates of MGMT promoter 




H02 – The correlation between IDH-1 mutation status and disease progression and 
survival is not affected by covariates MGMT promoter methylation, age, KPS, surgery 
for resection, and chemotherapy at progression. 
H12 - The correlation between IDH-1 mutation status and disease progression and 
survival is affected by covariates MGMT promoter methylation, age, KPS, surgery for 
resection, and chemotherapy at progression. 
Table 2 
 
Research Questions, Variables, and Statistical Methods 
Research 
Questions 
Dependent Variable Independent Variables Statistical 
Method 
Variable Measurement Variable Measurement 
Is there a 
significant 
difference in 



















































Dependent Variable Independent Variables Statistical 
Method 




































































>70 or < 70 
Yes or No 
 





The Cox proportional-hazards model was used to assess the effect (hazard ratio) 
of IDH-1 mutation status on time to disease progression and survival. In addition, 
Kaplan-Meir curves were generated to obtain survival rate for patients with and without 
the IDH-1 mutation. A Cox regression analysis was conducted to test the effects of key 
covariates (i.e., MGMT promoter methylation, age, KPS, surgery for resection and 
chemotherapy at progression) on disease progression and survival. Cox proportional 




clinical studies that investigate time-to-event outcomes like death and disease 
progression, which were also used in this study (Delgado et al., 2014; George et al., 2014; 
Koletsi & Pandis, 2017). Similarly, the Kaplan-Meir estimation is commonly used for 
survival analysis and to compare the survival distribution of two groups (George et al., 
2014). Cox proportional hazard model is also considered appropriate for time-to-event 
based studies because its regression analysis allows to evaluate the independent 
predictive value of selected covariates on the outcome measures like survival and time to 
disease progression (Delgado et al., 2014; George et al., 2014; Koletsi & Pandis, 2017). 
Since the study aimed to look at the effect of key covariates on disease progression and 
overall survival in GBM patients, Cox regression analysis was considered the most 
appropriate statistical method to assess the effect of selected covariates.    
Research in GBM is focused on molecular, genetic, epigenetic, and 
immunological markers in GBM, not only to better classify the disease but also to 
evaluate the prognostic value of these markers in terms of disease outcomes (Omuro & 
DeAngelis, 2013). Researchers are also evaluating the role of clinical prognostic factors, 
such as age at diagnosis, tumor site, surgical resection and its timing, KPS, and 
chemotherapeutic regimens, in the disease outcome. There are complex interactions 
between these molecular and clinical prognostic factors and appropriate adjustments must 
be made when evaluating the role of any specific factor for its prognostic value. This 
study took similar considerations into account in its design. The literature review 
conducted for this project suggested that MGMT promoter methylation (molecular 




factors) would be important covariates when comparing the PFS and OS of rGBM 
patients with and without IDH-1 mutation.  
Cox proportional hazard analysis was conducted to determine the effect of IDH-1 
mutation on OS and PFS utilizing the hazard ratio. Hazard ratio (HR) is used to interpret 
the Cox model and it is defined as the predicted hazard function in relation to two 
different conditions of a predictor variable (Delgado et al., 2014; George et al., 2014; 
Koletsi & Pandis, 2017). A hazard ratio of greater than one and less than one respectively 
indicates that the event is more likely or less likely to occur, whereas a HR of one 
indicates that the predictor has no effect on the hazard of the event (George et al., 2014). 
In this study the hazard ratio of IDH-1 mutation status on OS or PFS was determined by 
this model. Cox regression analysis was also conducted to test the effects of other key 
covariates on OS and PFS. Kaplan-Meir method was also used to determine the survival 
rate between the IDH-1 mutated and wildtype groups.  
Cox regression assumes proportional hazard and this assumption must be satisfied 
to ensure proper interpretation of the data using this model (Delgado et al., 2014; George 
et al., 2014; Koletsi & Pandis, 2017). While there may be a change over time in the 
underlying hazard, the model assumes proportional hazards for the values of predictors, 
which may be affected by time-varying covariates (George et al., 2014). Most of the 
covariates selected for this study (e.g., MGMT promoter methylation status, surgery for 
resection, and chemotherapy at recurrence) were categorical and did not affect the 
proportional hazard assumption of the regression model. One of the covariates selected 




affect the proportional hazard assumption of the regression model. Since KPS as a 
covariate did not have any effect on the OS, no additional methods were used to test the 
proportional hazard assumption for example, defining this covariate as a time-dependent 
covariate in the SPSS and then run the Cox regression with both time-fixed and time-
dependent covariates (Delgado et al., 2014).   
Threats to Validity 
The study was designed as a retrospective cohort study based on quantitative data 
collected on adult GBM patients at select hospitals in Massachusetts that is, BWH and 
SVH. These hospitals were selected to make the research feasible through ease of 
collaboration with oncologists at these centers and better access to EMR, which required 
the researcher to go through training at these hospitals. This approach would not have 
been possible if too many cancer centers had been selected, particularly in other states. 
The two centers were selected to ensure appropriate representation of the population 
within the state. Although no GBM patients at SVH met the inclusion criteria of having 
documented recurrence and IDH-1 mutation status, the BWH database included patients 
that were treated at or referred from other major hospitals in Massachusetts that is, 
Massachusetts General Hospital (MGH), Beth Israel Deaconess Center (BIDC), Dana 
Farber Cancer Institute (DFCI), Vermont Health Network (VHN), and Wentworth 
Douglass Hospital (WDH); therefore, study sample comprised of patients from multiple 
centers across the state. In addition, there is no evidence to suggest that the 
pathophysiology and clinical course of GBM would be different across the United States 




previously reported demographic information for GBM patients suggesting that 
appropriate and representative sample of GBM was included in this study (Ostrom et al., 
2018). Furthermore, EMR provides detailed clinical data that is relevant for outcomes 
research and is now increasingly used in clinical oncology and epidemiology studies (Lau 
et al., 2011); therefore, the risk to external validity was considered minimal for this study. 
In terms of internal validity, the study assumed that the patient data in the EMR 
was collected and entered in a reliable and accurate manner, particularly for the key 
variables. This assumption was appropriate considering the robust processes and standard 
operating procedures that each participating hospital have in place to ensure data 
integrity. It was not feasible to conduct an independent audit of the data due to hospital 
policies, magnitude of the database, and patient privacy concerns under the HIPAA 
(Rights (OCR), 2009). The other key assumption in context of internal validity was 
regarding the clinical assessment of recurrence and disease progression in GBM patients. 
While radiographic imaging was used as an objective measure to determine recurrence 
and progression of disease, the assessment was still made by a clinician. GBM patients 
are under the care of trained neurooncologists and such radiographical assessments are 
part of regular clinical practice, including oncology. 
Cohort studies may also be susceptible to selection, information, and comparison 
bias and as such can affect internal validity (Euser et al., 2009). Studies that include 
objective assessment of exposure and outcome adequately addresses these potential 
biases. In terms of selection bias, the inclusion of the GBM subjects in the study with the 




having the outcome of interest (disease progression and survival). Moreover, the 
diagnosis of GBM, both initial and recurring, were based on radiographic assessment and 
therefore it eliminated the selection bias due to differential referral or diagnosis (Euser et 
al., 2009). Similarly, information bias due to misclassification was unlikely since 
presence or absence of IDH-1 mutations is made by established laboratory diagnostic 
test. The use of objective measures for key independent and dependent variables also 
addressed any potential concern of construct validity that requires use of correct 
instruments and accurate measures of key variables (Strauss & Smith, 2009).  
Considering that the prognostic value of the IDH-1 mutation for the rGBM 
patients in this study was determined by comparing outcomes like time to disease 
progression and mortality, the confounding variables were factored in as covariates in the 
final data analysis. Cox regression analysis were conducted to address this limitation and 
to evaluate the effect of these confounding variables on the outcome of interest. The 
small sample size did not allow regression analysis after matching the groups for these 
covariates. Inability to match groups for confounding variables is a general limitation and 
challenge that researchers face when conducting research in a rare disease like GBM. In 
rare diseases, the sample size is relatively small to begin with and patient heterogeneity 
makes it difficult to adjust for all confounding variables while still maintaining a 
reasonable sample size for statistical analysis.  
Ethical Procedures 
The study was conducted under the appropriate oversight of Institutional Review 




of an approved GBM protocol (protocol number: 2015P002352) under the supervision of 
collaborating and principal investigator, Dr. Timothy Smith, Director, Computational 
Neuroscience Outcomes Center and Assistant Professor of Neurosurgery, Harvard 
Medical School. Similarly, approval was obtained from SVH IRB (email communication 
dated July 09, 2019 – submitted to Walden University for IRB approval) to access EMR 
data under the supervision of collaborating investigator Dr. Daniyal Siddiqui, Chief, 
Division of Hematology and Medical Oncology. A brief outline of the proposed research 
study was submitted to both collaborating oncologists and these clinicians facilitated 
institutional/IRB approval. All required training at BWH was completed and this training 
was also accepted by SVH prior to accessing the EMR data. Training courses for BWH 
included HIPAA, Protecting Patient Privacy, and Ethical Standards along with other 
general courses like Hazard Communication, Patient Care Assessment and Patient Safety. 
These courses were administered by HealthStream® and a certificate was issued upon 
successful completion of each course. Institutional Review Board approval was also 
obtained from Walden University (approval number: 08-19-20-0036388). Confidentiality 
of retrieved EMR data was maintained by ensuring that the data were not disclosed to any 
unauthorized user at any time and any data that were not properly de-identified was held 
with Drs. Smith and Siddiqui at the hospital with limited access by only authorized 
individuals on their team. Raw data with patient identifiable information were stored with 
Drs. Smith and Siddiqui at their respective hospitals and will be appropriately destroyed 
after the completion of this dissertation. Further precautions were taken to safeguard 




for example, medical record number was used for each subject included in the study 
rather than the use of name or initials. De-identified data were entered in the Excel sheet 
and subsequently uploaded in the SPSS software for the purposes of data analysis.  
Summary 
This chapter provided an overview of the methodological approach that was used 
for the study. It defined the key independent variable (IDH-1) and dependent variables 
(PFS and OS) that were selected for the study along with important covariates that were 
considered in the data analysis. The overall study design, including study population, 
sampling method, and inclusion criteria was defined in context of the overall scope of the 
study. Potential threats to external and internal validity were also addressed. While the 
study was conducted only at two major hospitals in Massachusetts, threat to external 
validity was considered minimal because: a) the BWH database was a combined database 
of BWH and MGH and included patients referred to these hospitals from other centers in 
the region as well; and b) there is no evidence to suggest that the pathophysiology and 
clinical course of GBM is different across the United States. Similarly, the objective 
measures and assessment used for both dependent and independent variables minimized 
the threat to internal and construct validity. A brief description of the statistical method 
was also provided; Cox proportional hazard model and regression analysis were used to 
interpret the study results and address specific research questions and hypothesis. The 




Chapter 4: Results 
Introduction 
The purpose of this study was to determine whether isocitrate dehydrogenase-1 
(IDH-1) mutation is a prognostic factor in recurrent glioblastoma (rGBM) considering 
other molecular and clinical prognostic factors as covariates. In a retrospective cohort 
study, time to disease progression or death from first recurrence was evaluated in rGBM 
patients with IDH-1 mutated and wild-type tumors. The effect of key variables (i.e., O6-
methylguanine-DNA methyl-transferase (MGMT) promoter methylation, age, Karnofsky 
Performance Score (KPS), surgery and/or chemotherapy at progression) was evaluated on 
the correlation between IDH-1 mutation status and disease progression and survival. The 
research questions and hypothesis that this study intended to answer were:  
RQ1: Is there a significant difference in time to disease progression and overall survival 
after first recurrence between rGBM patients with IDH-1 mutation and those without 
IDH-1 mutation? 
H01: Based on IDH-1 mutation status, there is no statistically significant difference in the 
time to disease progression and/or overall survival of rGBM patients. 
H11: Based on IDH-1 mutation status, there is a statistically significant difference in the 
time to disease progression and/or overall survival of rGBM patients. 
RQ2: Is the correlation between IDH-1 mutation status and disease progression and 
survival after first recurrence affected by the covariates of MGMT promoter methylation, 




H02 – The correlation between IDH-1 mutation status and disease progression and 
survival is not affected by covariates MGMT promoter methylation, age, KPS, surgery 
for resection, and chemotherapy at progression. 
H12 - The correlation between IDH-1 mutation status and disease progression and 
survival is affected by covariates MGMT promoter methylation, age, KPS, surgery for 
resection, and chemotherapy at progression. 
This chapter provides an overview of how the actual data collection process went 
during the research study, particularly focusing on some of the challenges and limitations 
that were not anticipated prior to the start of data collection. The descriptive demographic 
characteristics of the study population is also discussed along with the external validity of 
the data. Data collection section is followed by detailed study results including statistical 
analysis organized by research questions and hypothesis. Additional post-hoc analyses, 
that were conducted based on the findings from primary analysis, are also presented in 
the results section. Answers to the key research questions are then summarized at the end 
of the chapter. 
Data Collection  
The target population consisted of adult subjects with confirmed diagnosis of 
GBM and the study was based on secondary analysis through retrospective chart review 
of quantitative data collected on these subjects at select hospitals in Massachusetts. Data 
was collected from Electronic Medical Records (EMR) of the Brigham and Women’s 
Hospital (BWH), which turned out to be a combined database of BWH and 




MGH database also included patients that were referred to these centers from Beth Israel 
Deaconess Center (BIDC), Dana Farber Cancer Institute (DFCI), Vermont Health 
Network (VHN), and Wentworth Douglass Hospital (WDH). That database was searched 
for the study population and corresponding study-variables of interest during the period 
of 2008 and 2020.  
The major unanticipated challenge faced was that the databases were not 
searchable for disease specific “key-terms” like GBM or rGBM as initially planned. 
Rather, the databases could be searched only through a Research Patient Data Repository 
(RPDR) query using the International Classification of Disease-10 (ICD-10) code and 
GBM or rGBM does not have a specific ICD-10 code that could have been used to search 
the database. Instead, ICD-10 code C71 for “malignant neoplasm of the brain” had to be 
used but it includes other cancers of the brain besides GBM. As anticipated the search 
based on ICD-10 code C71 resulted in approximately 1200-1500 cases that included all 
neoplasms of the brain. It would not have been feasible to review individual patient 
records of all these cases to identify patients that would qualify for inclusion in the study. 
To make the database search manageable, the following strategy was used instead to 
identify patients based on the key variables of the study that is, IDH-1 mutation status 
and GBM patients with documented recurrence of their disease; therefore, the database 
was first queried for all patients who had been tested for IDH-1 mutation and this search 
yielded a total of 588 cases. Since IDH-1 mutation can be of interest in a variety of 
oncologic conditions (e.g., myeloid leukemia, breast cancer, lung cancer, etc.) (Bledea et 




applied to these 588 cases to further narrow the cases to relevant study population and 
this step reduced the sample size to 405 cases. In the final step, individual patient records 
for all 405 cases were reviewed and per the inclusion/exclusion criteria those patients that 
had non-glioblastoma tumors or GBM patients with no documented evidence of 
recurrence were excluded from the dataset.  This strategy resulted in a final sample size 
of 177 cases, whose charts were then reviewed in detail to collect all relevant information 
for detailed analyses to address the research questions. GBM is a rare disease and it was 
anticipated that the overall sample size for the study is going to be small. The 
inclusion/exclusion criteria of having only rGBM patients that have IDH-1 testing result, 
narrowed the overall study population; however, the sample size still exceeded the 
sample size of 108 that was estimated a priori using G*Power3 to detect a small effect 
size at an expected power of .90 and alpha of .05 (Faul et al., 2007). 
The baseline demographic characteristics of the population was not different from 
the final dataset since this was a retrospective cohort study. Data on age, gender, ethnic 
background was collected as part of the study and is described in the results section. The 
final dataset also did not change the minimal risk to external validity that was assumed 
prior to data collection. The study was initially planned based on two centers (i.e., BWH 
and SVH) and while SVH did not contribute any relevant cases to the study, the database 
of BWH was a combined database of BWH and MGH and this combined database also 
included patients that were referred to these hospitals from other major medical 
institutions and networks (i.e., BIDC, DFCI, VHN, and WDH) in Massachusetts; 




While caution needs to be taken in the generalizability of the data and results to the 
broader U.S. population, there is no evidence to suggest that the pathophysiology and 
clinical course of GBM would be different across the U.S.; therefore, it is anticipated that 
the results of this study provide fair representation of the overall rGBM patient 
population in the U.S. 
The univariate analyses indicated that IDH-1 is not a prognostic factor in 
recurrent GBM albeit with some data limitations. Multivariate analyses with selected 
molecular and clinical covariates were conducted to complete the planned analyses and to 
determine if the results were independent of other variables selected in the study. These 
multivariate analyses also indicated that IDH-1 is not a prognostic factor in rGBM within 
the boundaries of this study. Post-hoc analyses were conducted to evaluate the role of 
IDH-1 mutation over the entire GBM disease span and to compare the results of this 
study in context of the existing body of knowledge on the role of IDH-1 mutation status 
in GBM and rGBM.  
Results 
Descriptive Statistics 
  This section provides: a) general information on the demographics and key 
variables of the study population; and b) primary data collected on progression-free 







Demographic and Key Study Variables 
The general demographic information and distribution frequency of key study 
variables are summarized in Table 3. The study population was predominantly White 
males of 65 years or younger; the median age of the study population was 60 (25, 87) 
years. Majority of patients’ tumors had wildtype IDH-1 (92%) whereas MGMT promoter 
methylation status was somewhat evenly distributed between methylated (41%) and 
unmethylated (51%). Clinical-based variables indicate that 60% of study population had a 
KPS of >70 and patients that had surgery or received chemotherapy at recurrence were 
31% and 84%, respectively. Although the patients in the database were from six different 
institutions, most of the patients (88%) were treated at MGH.  
Table 3  
 
General Demographics and Key Variables 
Attribute N Percentage 
Age   
<65 years 120 67.8% 
>65 years 57 32.2% 
Gender   
males 117 66.1% 
females 60 33.9% 
Race   
whites 150 84.7% 
blacks 3 1.7% 
Hispanics 2 1.1% 
Asians 3 1.7% 
American Indians 2 1.1% 
others 8 4.5% 
not provided 9 5.1% 
IDH-1   
wildtype 163 92.1% 
mutated 13 7.3% 
missing 1 0.6% 
MGMT    




Attribute N Percentage 
   
unmethylated 90 50.8% 
missing 15 8.5% 
KPS   
<70 57 32.2% 
>70 107 60.5% 
missing 13 7.3% 
Surgery at Recurrence   
yes 37 31% 
no 81 68% 
Chemotherapy at Recurrence   
yes 102 84.3% 
no 19 15.7% 
Hospitals   
BWH 2 1.1% 
MGH 156 88.1% 
DFCI 15 8.5% 
BIDMC 2 1.1% 
VHN 1 0.6% 
WDH 1 0.6% 
SVH 0 0% 
 
Since IDH-1 mutation status is the key variable of the study, the distribution of 
other key variables selected for the study was also assessed in context of IDH-1 mutation 
status. Data tabulated for each variable in Table 4 excludes those subjects with missing 
values for the stated variable. As anticipated the overall number of patients with tumors 
carrying IDH-1 mutation was small (13%) with equal number of males and females and 
all of these patients were <65 years. MGMT promoter methylation status was equally 
distributed in the IDH-1 positive patients and most of them had either chemotherapy or 




Table 4  
 
Demographic Information and Key Covariates in Context of IDH-1 Mutation Status 
Variables IDH-1 Wildtype IDH-1 Mutated Total 
Age 
   
<65 107 (60%) 13 (7%) 120 (68%) 
>65 57 (32%) 0 57 (32%) 
Gender 
   
male 110 (62%) 7 (4%) 117 (66%) 
female 54 (31%) 6 (3%) 60 (34%) 
MGMT  
   
methylated 64 (39%) 7 (54%) 71 (44%) 
unmethylated 85 (52%) 5 (38.5%) 90 (56%) 
KPS 
   
<70 54 (33%) 3 (2%) 57 (35%) 
>70 96 (59%) 10 (6%) 106 (65%) 
Surgery at 
recurrence 
   
yes 33 (28%) 4 (3%) 37 (31%) 
no 78 (66%) 3 (2%) 81 (69%) 
Chemotherapy at 
recurrence 
   
yes 94 (78%) 7 (6%) 101(84%) 
no 19 (16%) 0 19 (16%) 
 
Progression-Free Survival and Overall Survival 
Time in months was calculated to determine the median progression-free survival 
(PFS) and median overall survival (mOS) in patients with wildtype and mutated IDH-1 
gene (Table 5). PFS was defined as time from initial diagnosis to first recurrence and 
time from first recurrence to subsequent recurrence. Survival was defined as time from 
initial diagnosis to death and time from first recurrence to death. Data suggests that 
compared to time from initial diagnosis, median PFS and OS is shorter in the recurrent 




counterparts, patients with IDH-1 mutation seems to have better outcomes in median PFS 
and OS except for time-to-death from first recurrence.   
Table 5  
 





















    
Mdn (months) 8 4 13 4.5 
SD 9 5 11 4 
N 116 42 50 42 
Mutated 
    
Mdn (months) 12 6.5 25 3 
SD 15 2 23 3.5 
N 7 2 3 3 
 
Statistical Analyses 
Statistical analyses first focused on the specific research questions and then 
additional analyses were conducted to gain an understanding of the role of IDH-1 
mutation in the overall disease prognosis in GBM. Cox regression assumes proportional 
hazard and this assumption must be satisfied to ensure proper interpretation of the data 
using this model (Delgado et al., 2014; George et al., 2014; Koletsi & Pandis, 2017). 
Almost all the variables selected for this study (i.e., IDH-1 mutation status, MGMT 
promoter methylation status, surgery for resection, and chemotherapy at recurrence) are 





Research Question 1 
The first research question (RQ1) was: Is there a significant difference in time to 
disease progression and overall survival after first recurrence between rGBM patients 
with IDH-1 mutation and those without IDH-1 mutation? Univariate analysis of variance 
(ANOVA) was conducted to evaluate the difference between the IDH-1 mutated and 
wildtype groups for PFS (i.e., time from first recurrence to subsequent recurrence) and 
survival (i.e., time from first recurrence to death) (Table 6). Homogeneity of variance 
assumption (Levene’s test) was met for all covariates in the ANOVA. The analyses 
indicated that there was no statistically significant difference in either PFS [F(1, 789.3) = 
.03, p = .86] or survival [F(1, 668.6) = .04, p = .83].  
Table 6  
 
IDH-1 Mutation as Prognostic Factor in Recurrent GBM 














668.57 1 668.57 .04 .83 .001 
  
Survival analysis were also conducted to test if there was a difference between the 




significant difference noted in median survival times utilizing Kaplan-Meir cumulative 
survival analysis (Table 7 and Figure 2) and Cox regression analysis (Table 8).  
Table 7  
 
Median Survival Time and IDH-1 Mutation Status in Recurrent GBM 




















Table 8  
 





















 Since there was no statistically significant difference between IDH-1 wildtype and 
mutated groups in PFS [F(1, 789.3) = .03, p = .86] and survival (HR 1.3; 95% CI, .39, 
4.24; p = .67), the null hypothesis for RQ 1 was not rejected (i.e., H01: Based on IDH-1 
mutation status, there is no statistically significant difference in the time to disease 
progression and/or overall survival of rGBM patients).  
Research Question 2 
The second research question (RQ2) was: Is the correlation between IDH-1 
mutation status and disease progression and survival after first recurrence affected by the 
covariates of MGMT promoter methylation, age, KPS, surgery for resection, and 
chemotherapy at progression. While the overall comparison of rGBM patients with IDH-
1wildtype and mutated genes did not indicate any difference in PFS and survival, it was 
important to determine if there is an effect, or lack thereof, of selected covariates on these 
outcomes. Both univariate and multivariate regression analyses was conducted evaluating 




(survival) with predictors of age, gender, MGMT methylation status, KPS, and surgery or 
chemotherapy at recurrence. 
In terms of PFS, the univariate analysis indicated that none of the covariates had 
any significant contribution to the outcome (Table 9). Similarly, there was no significant 
difference in PFS when factoring in all the predictors, F(6, 198713) = 1.23, p = .31 and 
none of the covariates were found to be significant contributors in PFS (Table 10). 
Table 9 
 
IDH-1 Mutation and PFS in Recurrent GBM – Effect of Covariates (Univariate Analyses) 




F Significance Partial 
Eta 
Squared 
IDH-1 789.30 1 789.30 .30 .86 .00 
Age 40785.33 1 40785.33 1.44 .24 .03 
Gender 68991.50 1 68991.50 2.50 .12 .05 
MGMT 
methylation 
69180.32 1 69180.32 2.32 .14 .06 








IDH-1 Mutation and Progression Free Survival in Recurrent GBM – Effect of Covariates 
Variable B SE t Significance 95% CI 




Variable B SE t Significance 95% CI 
Gender -61.52 56.94 -1.08 .29 -177.37, 54.319 
MGMT 
Methylation 
79.77 55.02 1.45 .16 -32.15, 191.71 




12.06 125.29 .09 .92 -242.86, 266.98 
 
In terms of survival, the univariate analysis indicated that none of the covariates 
had any significant contribution to the outcome (Table 11). Similar to PFS, there was no 
statistically significant difference noted for survival when factoring in all the predictors, 
F(6, 99178.32) = 1.17, p = .34 and none of the covariates were found to be significant 
contributors in survival (Table 12). 
Table 11 
 
IDH-1 Mutation and Survival in Recurrent GBM – Effect of Covariates (Univariate 
Analyses) 




F Significance Partial 
Eta 
Squared 
Age 16086.40 1 16086.40 1.08 .30 .02 
Gender 317.96 1 317.96 .02 .89 .00 
MGMT 
methylation 
25525.80 1 25525.80 1.74 .19 .04 














27120.25 1 27120.25 1.86 .18 .04 
 
Table 12  
 
IDH-1 Mutation and Survival in Recurrent GBM - Effect of Covariates 
Variable B SE t Significance 95% CI 
Age -45.69 45.50 -1.00 .32 -138.27, 46.88 
Gender 3.05 43.35 .07 .94 -85.14, 91.24 
MGMT 
Methylation 
76.36 45.59 1.67 .10 -16.39, 169.11 




37.38 57.99 .64 .52 -80.60, 155.36 
  
The null hypothesis for RQ2 (i.e., H02 – The correlation between IDH-1 mutation 
status and disease progression and survival is not affected by covariates of age, gender, 
MGMT promoter methylation, KPS, surgery and/or chemotherapy at progression) was 
not rejected because: a) there was no significant difference between IDH-1 wildtype and 
mutated groups after factoring in covariates of age, gender, MGMT methylation status, 
KPS, and surgery and/or chemotherapy at recurrence for both PFS [F(6, 198713) = 1.23, 




showed any significant contribution to the PFS and survival after recurrence (Tables 10 
and 12, respectively).  
Post-hoc Analyses 
Post-hoc analyses focused on evaluating the role of IDH-1 mutation in PFS and 
overall survival (OS) from initial diagnosis that is, over the entire GBM disease span 
rather than after recurrence, which was evaluated as part of specific research questions. 
The intention was to: a) compare the data from this study with other limited studies 
conducted to evaluate the role of IDH-1 in GBM; and b) assess the underlying premise of 
this study that while IDH-1 mutation may be a prognostic factor in GBM if evaluated 
from initial disease diagnosis, it may not be of prognostic significance once the disease 
recurs or rGBM. The PFS and OS for the purposes of this post-hoc analyses was defined 
as days from initial diagnosis to first recurrence and days from initial diagnosis to death, 
respectively. 
Univariate analysis of variance (ANOVA) was conducted to evaluate the 
difference between the IDH-1 mutated and wildtype groups for PFS and OS (Table 13). 
The analyses indicated that while there was no statistically significant difference in PFS 
[F(1, 189074.27) = 2.26, p = .14], the difference in OS was statistically significant [F(1, 







IDH-1 Mutation as Prognostic Factor in GBM 














724286.53 1 724286.53 5.50 .02 .01 
 
Survival analysis were also conducted to test if there was a difference between the 
two IDH-1 groups in terms of days from initial diagnosis to death. There was no 
significant difference noted in median survival times utilizing Kaplan-Meir cumulative 
survival analysis (Table 14 and Figure 3) and Cox regression analysis (Table 15). 
Table 14 
 
Median Survival Time and IDH-1 Mutation Status in GBM 


















































 Since a statistically significant difference was noted for OS (Table 13), both 
univariate and multivariate regression analysis were conducted evaluating days from 
initial diagnosis to death (OS) with predictors of age, gender, MGMT methylation status, 
KPS, and surgery and/or chemotherapy. In the univariate analysis, gender and age were 
found to be significant contributing covariates in OS and the covariate of age showed a 
strong trend (Table 16). In the multivariate analysis, there was a significant difference in 
OS when factoring in all the predictors, F(6, 2049021.89) = 2.48, p = .04; however, only 




IDH-1 Mutation and Overall Survival in GBM – Effect of Covariates (Univariate 
Analyses) 




F Significance Partial 
Eta 
Squared 
Age 393946.28 1 393946.28 2.85 .09 .05 
Gender 606677.90 1 606677.90 4.53 .04 .08 
MGMT 
methylation 
739158.35 1 739158.35 5.34 .02 .10 











IDH-1 Mutation and Overall Survival in GBM - Effect of Covariates 
Variable B SE t Significance 95% CI 
Age -141.56 142.20 -1.00 .33 -430.87, 147.74 
Gender -42.40 135.46 -.31 .76 -318.00, 233.19 
MGMT 
Methylation 
413.90 142.47 2.90 .007 124.04, 703.77 




132.31 181.23 .73 .47 -236.40, 501.02 
 
Based on these results, Cox regression analysis was conducted with both IDH-1 
mutation and MGMT methylation status in the model considering the significant 
contribution of the latter as a covariate in overall survival (Table 18). The analysis 
indicated that both IDH-1 mutation and MGMT methylation were negatively correlated 
with mortality and while IDH-1 mutation showed a strong statistical trend for its 
contribution in OS (HR .31; 95% CI, .08, 1.12; p = .07), contribution of MGMT 
methylation in OS was statistically significant (HR .38; 95% CI, .18, .80; p = .01); 
however, this prognostic effect of methylated MGMT promoter was not seen following 
disease recurrence in this study (HR .51; 95% CI, .23, 1.13; p = .10). The sample size of 
IDH-1 mutated group was not sufficient to do further subgroup survival analysis of 





Table 18  
 



























 Cox regression analyses were also conducted with IDH-1 mutation and gender 
and age in the model. The analysis indicated that contribution of gender was not 
statistically significant in OS (HR 1.54; 95% CI, .82, 2.90; p = .18) but age was 
negatively correlated with mortality and showed a strong statistical trend (HR .57; 95% 
CI, .31, 1.04; p = .07) for its contribution in OS (Tables 19 and 20).  
Table 19 
 

















.59 .65 .84 1 1.81 
(.51, 6.44) 
.36 


























.701 .619 1.28 1 2.01 
(.60, 6.77) 
.26 





Research questions for this study aimed to assess the prognostic value of IDH-1 
mutation in recurrent GBM. The following specific research questions were postulated 
for the study purpose and the results related to these questions are hereby summarized: 
• The first research question was: Is there a signification difference in time to disease 
progression and overall survival after first recurrence between rGBM patients with IDH-1 
mutation and those without IDH-1 mutation? Time to disease progression or progression 
free survival (PFS) was defined as time from first recurrence to second recurrence and 
survival was defined as time from first recurrence to death. The results of the study 
indicated that there was no statistically significant difference in either PFS [F(1, 789.3) = 
.03, p = .86] or survival [F(1, 668.6) = .04, p = .83] of rGBM patients with IDH-1 
wildtype and mutated tumors. Furthermore, survival analysis also indicated statistically 
insignificant difference (HR 1.3; 95% CI, .39, 4.24; p = .67) between the two groups; 




on IDH-1 mutation status, there is no statistically significant difference in the time to 
disease progression and/or overall survival of rGBM patients).  
• The second research question was: Is the correlation between IDH-1 mutation status and 
disease progression and survival after first recurrence affected by the covariates of 
MGMT promoter methylation, age, KPS, surgery for resection, and chemotherapy at 
progression. While the overall comparison of rGBM patients with IDH-1wildtype and 
mutated tumors did not indicate any difference in PFS and survival, it was important to 
determine if there is an effect, or lack thereof, of selected covariates on these outcomes. 
The results of the study indicated that there was no significant difference in PFS [F(6, 
198713) = 1.23, p = .31] and OS [F(6, 99178.32) = 1.17, p = .34] after factoring in all the 
predictors and none of the covariates showed any significant contribution to either PFS or 
survival after recurrence; therefore, the null hypothesis of this research question was not 
rejected (i.e., H02: The correlation between IDH-1 mutation status and disease 
progression and survival is not affected by covariates MGMT promoter methylation, age, 
KPS, surgery for resection, and chemotherapy at progression). 
The role of IDH-1 mutation as a prognostic factor in GBM remains unclear, 
particularly in the recurrent disease. The results of this study, albeit with its limitations, 
suggests that IDH-1 mutation is not a prognostic factor in recurrent GBM. Post-hoc 
analyses conducted in this study evaluated the prognostic value of IDH-1 mutation over 
the entire GBM disease span with the intention to: a) compare the data from this study 
with other limited studies conducted to evaluate the role of IDH-1 in GBM; and b) assess 




factor in GBM if evaluated from initial disease diagnosis, it may not be of prognostic 
significance once the disease recurs defined as rGBM. The next chapter presents the 
findings of this study in context of the existing body of knowledge and interprets the 
results considering the limitations of the study. The following chapter also includes 
implications of this study, contribution to a positive social change in relation to clinical 




Chapter 5: Discussion, Conclusion, and Recommendations 
Introduction 
The purpose of this study was to determine whether IDH-1 mutation is a 
prognostic factor in rGBM considering other molecular and clinical prognostic factors as 
covariates. The prognostic value of IDH-1 mutation is debated even following initial 
diagnosis of GBM since studies have demonstrated both weak and strong association 
between IDH-1 mutation and overall survival (Amelot et al., 2015; Mukasa et al., 2012; 
Zou et al., 2013). A few studies have examined the role of IDH-1 mutation in rGBM, but 
only in the clinical trial setting and with inconclusive results (Mandel et al., 2016; Taal et 
al., 2014). This study was a retrospective cohort study based on quantitative data 
collected through retrospective chart reviews of adult patients diagnosed with GBM at 
select hospitals in Massachusetts. Time to disease progression or death from first 
recurrence was evaluated in rGBM patients with IDH-1 mutated and wild-type tumors. 
The effect of key variables (i.e., MGMT promoter methylation, age, KPS, surgery for 
resection, and chemotherapy at progression) was also evaluated in context of the 
association between IDH-1 mutation status and disease progression and survival. The 
results of this study indicated that there was no statistically significant difference in either 
time to disease progression or survival of rGBM patients with IDH-1 wildtype and 
mutated tumors. Similarly, the results also indicated that there was no significant 
difference in time to disease progression or survival after factoring in all the predictor 
variables and none of these variables showed any significant contribution to either time to 




Interpretation of the Findings 
The characteristics of the study population were found to be generally consistent 
with the existing knowledge on GBM. In the study database after adjusting for IDH-1 
mutation, there were approximately 44% GBM patients among patients diagnosed with 
neoplasm of the brain which is consistent with earlier reports that indicate that GBM 
accounts for approximately 48% of all primary malignant brain tumors (Quick Brain 
Tumor Facts, n.d.). The study population was predominantly White (85%) males (66%) 
of 65 years or younger; the median age of the study population was 60 (25, 87) years. 
These findings were consistent with previous reports that indicate a median age of 65 
year at diagnosis of GBM with higher incidence in adults aged 75-85 years (Ostrom 
2018). Similarly, incidence rate of GBM is considered 1.6 times higher in males and 
approximately twice as greater in Whites than Blacks (Ostrom et al., 2018). Majority of 
patients’ tumors in this study had wildtype IDH-1 (92%) whereas MGMT promoter 
methylation status was somewhat evenly distributed between methylated (41%) and 
unmethylated (51%). These results were consistent with previous reports indicating that 
approximately 95% of primary GBM tumors have wildtype IDH-1 and about 50% have 
methylated MGMT promoters (Lieberman, 2017; Olar & Aldape, 2014; Yang et al., 
2015).    
The primary objective of this study was to determine the prognostic value of IDH-
1 mutation in recurrent GBM that is, progression free survival and survival following first 
recurrence. The study results indicated that there was no statistically significant 




4.24; p = .67) of rGBM patients with IDH-1 wildtype and mutated tumors. The results of 
this study appears to be consistent with couple of studies that have examined the role of 
IDH-1 mutation in rGBM, albeit in a clinical trial setting, that showed that IDH-1 
mutation did not result in prolonged PFS or survival compared to IDH-1 wild-type 
tumors in recurrent GBM (Mandel et al., 2016; Taal et al., 2014). While the number of 
IDH-1 mutated patients in this study was approximately three times more (13 patients) 
compared to the five rGBM patients with mutated IDH-1 included in the study by Mandel 
(2016) and Taal (2014), analyses is still overall limited by the small number of IDH-1 
mutated patients and results must be considered with caution. The results of the study 
also indicated that selected predictors (i.e., MGMT promoter methylation status, age, 
KPS, and surgery and/or chemotherapy at recurrence) do not affect PFS and survival 
following disease recurrence. The effects of these predictors on PFS and survival have 
not been studied in rGBM and multiple factors must be considered to evaluate the role of 
these predictors in disease prognosis. For example, recent studies have highlighted the 
timing of resection and its association with PFS and survival in GBM with a lower risk of 
death noted with repeat resection without taking the timing of resection into account but a 
higher risk of death was noted after adjustment for the timing of resection (Goldman et 
al., 2018; Y.-H. Zhao et al., 2019). Considering the small sample size of IDH-1 mutated 
group, it was not feasible to conduct further subset analyses by matching the two groups 
with specific parameters for each selected covariate. Although the results of the study 
indicated that the selected covariates (i.e., age, MGMT promoter methylation status, 




recurrent GBM, the complexity of disease pathophysiology and interactions between 
molecular and clinical markers of prognosis make it challenging to conclusively 
determine effect of these factors in GBM, including rGBM (Audureau et al., 2018; 
Chaichana et al., 2013; Clarke et al., 2011).  
The post-hoc analyses also compared the effect of IDH-1 mutation on PFS and 
overall survival (OS) from initial diagnosis to first recurrence and death. The analyses 
indicated that while there was no statistically significant difference in PFS [F(1, 
189074.27) = 2.26, p = .14], the difference in OS was statistically significant [F(1, 
724286.53) = 5.50, p = .02]. Furthermore, Cox regression analysis was conducted with 
both IDH-1 mutation and MGMT methylation status in the model considering the 
significant contribution of the latter as a covariate in overall survival. The analysis 
indicated that both IDH-1 mutation and MGMT methylation were negatively correlated 
with mortality and while IDH-1 mutation showed a strong statistical trend for its 
contribution in OS (HR .31; 95% CI, .08, 1.12; p = .07), contribution of MGMT 
methylation in OS was statistically significant (HR .38; 95% CI, .18, .80; p = .01). The 
strong trend, but inconclusive evidence of association, noted in this study for the 
prognostic value of IDH-1mutation from initial diagnosis to death seems to be reflective 
of previously reported data that suggests both weak and strong association between IDH-
1 mutation and overall survival (Amelot et al., 2015; Chen et al., 2016; Mandel et al., 
2016; Mukasa et al., 2012; Xia et al., 2015; Zou et al., 2013). A larger sample size of 
patients with IDH-1 mutation in this study may have provided a clearer perspective on 




worth noting that some of the studies showing strong association between IDH-1 
mutation and overall survival did not adjust for some of key contributing variables, like 
MGMT promoter methylation status (Mandel et al., 2016). This study showed a 
statistically significant effect of MGMT promoter methylation status on OS from initial 
diagnosis and this finding is consistent with previous reports, including three meta-
analysis, that have shown that OS was significantly better in patients with methylated 
MGMT promoter (Olson et al., 2011; H. Zhao et al., 2016; Y.-H. Zhao et al., 2018). The 
prognostic effect of methylated MGMT promoter, however, was not seen following 
disease recurrence in this study. The prognostic value of methylated MGMT promoter in 
rGBM has been studied in combination with other factors like radiosurgery and 
researchers have suggested additional studies to specifically evaluate the role of MGMT 
promoter methylation status in rGBM (Kim et al., 2017). Cox regression analysis was 
also conducted with both IDH-1 mutation and age in the model considering the 
significant contribution of the latter as a covariate in the univariate analysis. The median 
age in the IDH-1 mutated group was 45 (35, 65) years. The analysis indicated that age 
was negatively correlated with mortality and showed a strong statistical trend for its 
contribution in OS (HR .57; 95% CI, .31, 1.04; p = .07). These results were consistent 
with previous findings that have reported age 50 years as the typical cut-off from the 
perspective of a prognostic value, with a higher risk of death seen in patients over 70 
years; however, the shorter survival rate for older GBM patients is most likely due to 
comorbidities and inability to tolerate the effects of the cancer itself and treatments like 




The study was aligned with the conceptual framework of outcomes research, 
particularly outcomes research in oncology as proposed by Lee (2000) and generally 
adopted by other researchers (Apolone, 2003; Fay et al., 2015; Kovvali, 2014; Lee et al., 
2000; Melamed et al., 2017; Roberts et al., 2019). Utilizing the outcomes measures of 
PFS and survival included in the outcomes research framework, the results of this study 
indicated that IDH-1 mutation was not a prognostic factor in rGBM. The results of this 
study contributed to the body of knowledge on the molecular and clinical prognostic 
factors that should be considered in the treatment and management of rGBM patients; 
therefore, it broadly addressed both the prediction rules and the treatment options as well 
as application aspect of the outcomes research framework (Lee et al., 2000). 
Limitations of the Study 
Even though the overall sample size of the study (177) exceeded the sample size 
of 108 that was estimated a priori for statistical analyses, these analyses were limited by 
the relatively small number of patients with mutated IDH-1 status (7.3%) and the results 
must be interpreted with caution. An overall small sample size, including number of 
patients with mutated IDH-1 status, was anticipated considering that GBM is a rare 
disease, testing for IDH-1 mutation status only recently became a standard practice after 
its inclusion in the classification of gliomas, and only 5% of primary GBM tumors have 
mutated IDH-1 (Lieberman, 2017; Miller et al., 2017; Olar & Aldape, 2014; Ostrom et 
al., 2018). These facts were evident in the data collected for this study where the original 
database included about 1500 patients with neoplasm of the brain, but the final study 




documented evidence of IDH-1 mutation status and disease recurrence. The results of this 
study would need to be interpreted in context of its limitations, but they could be 
considered reliable since these results were overall congruent with earlier reports, as 
discussed above, on the prognostic value of IDH-1 in GBM both from initial diagnosis 
and following recurrence.  
This study also met the parameters for external validity that were assumed prior to 
data collection and analyses. The study was planned at two clinical centers in 
Massachusetts, Brigham and Women’s Hospital (BWH) and St. Vincent Hospital (SVH), 
to ensure appropriate representation of the population within the state. Although no GBM 
patients at SVH met the inclusion criteria of having documented recurrence and IDH-1 
mutation status, the BWH database included patients that were treated at or referred from 
other major hospitals in Massachusetts that is, Massachusetts General Hospital (MGH), 
Beth Israel Deaconess Center (BIDC), Dana Farber Cancer Institute (DFCI), Vermont 
Health Network (VHN), and Wentworth Douglass Hospital (WDH). The age, gender, and 
ethnic characteristics of this study population was consistent with the previously reported 
demographic information for GBM suggesting that appropriate and representative sample 
of GBM was included in this study. Overall, this study is considered to have good 
external validity because there is no evidence to suggest that the pathophysiology and 
clinical course of GBM would be different across the United States, it included patients 
from multiple clinical centers across Massachusetts, and the demographic characteristics 
of these patients were consistent with previously reported demographic data for GBM 





The primary focus of this study was to evaluate the prognostic value of IDH-1 
mutation status in recurrent GBM taking into consideration other key predictors. The 
limited sample size particularly for IDH-1 mutated tumors in this study underscored the 
overall challenges of conducting studies in rare diseases like GBM and these challenges 
are further compounded with stricter inclusion exclusion criteria typically selected to 
limit the scope of the study. Following recommendations are proposed for future studies 
to further confirm the findings of this study: 
• A larger study sample size to ensure that there is a higher number of patients with 
mutated IDH-1 tumors in the overall study population of rGBM. Although this 
retrospective study relied on a database that had patient records from major hospitals in 
Massachusetts, the total number of patients with mutated IDH-1 tumors was still 
relatively small (7.3%). Considering that testing for IDH-1 mutation status only recently 
became a standard practice in GBM and only 5% of GBM tumors carry IDH-1 mutation, 
future studies would most likely have to be conducted as multicenter studies across the 
United States to increase the overall sample size thereby ensuring enough patients with 
mutated IDH-1 tumors. 
• The effect of predictors like age, MGMT promoter methylations status, KPS, and surgery 
or chemotherapy at recurrence on PFS and survival based on IDH-1 mutation status 
should be further evaluated in rGBM. Although the results of this study indicated that 
these predictors are not associated with PFS and survival based on IDH-1 mutation status, 




mutated patients; the two IDH-1 groups would have to be appropriately matched for these 
predictors to provide more conclusive evidence. 
• The results of this study indicated that methylated MGMT promoter was a key predictor 
of survival from initial diagnosis but not after disease recurrence. Previous studies have 
mainly focused on the prognostic value of MGMT promoter methylation status in GBM 
after initial diagnosis but not in recurrent GBM; therefore, future studies can further 
explore the prognostic value of MGMT promoter methylation in recurrent setting to 
confirm the results of this study. Recent studies have suggested that MGMT promoter 
methylation status may change over time and following relapse (Feldheim et al., 2019; 
Storey et al., 2019); therefore, future studies should also consider retesting of the MGMT 
promoter methylation status at recurrence.  
• In this study IDH-1 mutation was negatively correlated with mortality and showed a 
strong statistical trend for its contribution in overall survival from initial diagnosis (HR 
.31; 95% CI, .08, 1.12; p = .07). This finding is consistent with the previous reports that 
have shown both strong and weak association between IDH-1 mutation and overall 
survival (Amelot et al., 2015; Chen et al., 2016; Mandel et al., 2016; Mukasa et al., 2012; 
Xia et al., 2015; Zou et al., 2013). Additional studies with larger sample size are 
recommended to further investigate the correlation of IDH-1 mutation and overall 
survival in GBM. Consistent with previous studies, this study showed that methylated 
MGMT promoter is a key prognostic factor in overall survival of GBM patients from 




methylation status when evaluating the prognostic value of IDH-1 mutation status in 
overall survival.  
Implications 
It is anticipated that the results of this study will bring about a positive social 
change by affecting both patient treatment and health care practice in recurrent GBM. 
The presumed role of IDH-1 mutation as an overall prognostic factor upon initial 
diagnosis of GBM typically results in the selection of treatment modalities that are 
relatively aggressive, including a combination of resection, chemotherapy, and adjuvant 
therapy, with an intent to improve progression free survival and overall survival; 
however, this prognostic value of IDH-1 in recurrent GBM has not been extensively 
studied. The results of this study, albeit with its limitations, showed that IDH-1 mutation 
is not a prognostic factor in recurrent GBM; therefore, continuation of an aggressive 
treatment approach that is based on IDH-1 mutation status at initial diagnosis will most 
likely not confer any clinical or survival advantage following disease recurrence. 
Considering that there are significant risks associated with aggressive treatments like 
chemotherapy, the results of this study may mitigate unnecessary exposure of rGBM 
patients to the safety risks that are associated with treatments selected at initial diagnosis. 
It is anticipated that the results of this study will also contribute to a positive social 
change by informing the clinical practice guidelines to treat and manage GBM patients 
following disease recurrence. It should continue to advance the conversation on how 
prognostic factors like IDH-1 mutation may need to be considered differently in recurrent 




treatments should be considered when selecting an optimal treatment course for patients 
with recurrent GBM. Moreover, if these costly treatments that are a financial burden for 
both patients and health care system are not found necessary in the recurrent disease, then 
positive social change may also be affected over time through substantial savings in the 
overall health care costs associated with the management of GBM and rGBM. 
The results of this study underscored the relevance and utility of outcomes 
research in oncology (Lee et al., 2000) and it added to the existing evidence that 
prediction rules, treatment options, and application aspect of outcomes research 
framework can be appropriately utilized in future studies of similar purpose and scope. 
This study was designed as a retrospective cohort study based on data collected from 
electronic medical records and this study design is considered relevant for outcomes 
research (Lau et al., 2011). Retrospective cohort design was also selected for efficiency 
because a prospective study would have been costly and time-consuming making it 
impractical for this dissertation project; however, the results of this study do make a case 
for prospective studies in future to further evaluate the role of prognostic factors, 
including IDH-1 mutation, in recurrent GBM. The rare nature of this disease and 
complex interactions between molecular and clinical prognostic factors mainly limits the 
retrospective studies in terms of overall sample size, matching of the groups for 
contributing variables, and occurrence of events like disease progression and death 
needed for outcome analyses. Although a prospective study would take longer to 
complete, it may be better suited to address research questions by mitigating some of the 





Glioblastoma is an aggressive form of brain cancer that has a high recurrence rate 
and very poor prognosis (Ostrom et al., 2018). The prognostic value of various molecular 
markers (e.g., IDH-1 mutation, MGMT promoter methylation, etc.) and clinical factors 
(e.g., age, KPS, surgery and chemotherapy, etc.) has been studied in GBM after initial 
diagnosis but not as extensively in the recurrent GBM. Utilizing a retrospective cohort 
design and framework of outcomes research in oncology, this study evaluated the 
prognostic value of IDH-1 mutation in recurrent GBM in the context of key predictor 
variables of age, MGMT promoter methylation, KPS, and surgery and chemotherapy at 
recurrence. The results of this study indicated, albeit with its limitations, that IDH-1 
mutation was not a prognostic factor in recurrent GBM. The prognostic value of IDH-1 
mutation from initial diagnosis in this study was inconclusive consistent with previous 
reports. The results of this study also indicated that although methylated MGMT 
promoter was a strong prognostic factor from initial diagnosis as previously reported, it 
was not a prognostic factor in recurrent GBM. Overall, the results of this study suggest 
that the pathophysiology and prognosis of GBM may need to be considered differently at 
initial diagnosis and following disease recurrence. Molecular markers like IDH-1 
mutation and MGMT promoter methylation status are used as prognostic factors to make 
treatment decisions for GBM patients at initial diagnosis. The results of this study 
indicate that these molecular markers may not carry the same prognostic value after 
disease recurrence and treatment decision that are made based on these markers at initial 




are significant risks associated with aggressive treatments like combination of 
chemotherapies that are selected based on prognostic factors like IDH-1 mutation and 
MGMT promoter methylation at initial diagnosis, the results of this study may mitigate 
unnecessary exposure of rGBM patients to the safety risks that are associated with such 
treatments; therefore, it is anticipated that the results of this study will bring about a 
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